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1.1. The skin: structure and function 
The skin is the largest organ of the hu-
man body. The most important function 
is to form a barrier between the organism 
and the external environment. In this way 
the skin protects the individual from en-
vironmental influences such as mechani-
cal impacts, ultraviolet light, chemicals, 
or pathogenic microorganisms and as 
well as the unregulated loss of water and 
solutes (Jadoul, Bouwstra, and Préat 1999)
(Thomas and Finnin 2004) (Figure 1).
Skin consists of three main strata: the 
hypodermis, is the innermost layer, com-
posed of lipocytes that are arranged into 
fat lobules separated from one anoth-
er by fibrous septae, it offers the body 
thermal and mechanical protection; the 
upperlying dermis formed by collagen 
fibres, elastic tissue, ground substance 
and spread cells, mostly fibroblasts, it 
contains nerve endings, bood vessels 
and lymphatic vessels, it high irrigation 
ensures the nutrition of the skin cells; 
over the dermis and separated by the 
basement membrane, the epidermis is 
composed of different layers, depending 
on the state of keratinocyte differentia-
tion, where the stratum corneum is the 
uppermost layer. Keratinocytes are affect-
ed by a process of keratinisation, in which 
the cell differentiates from the basal layer 
(stratum basale), through the stratum spi-
nosum and stratum granulosum, to the 
stratum corneum (Sinico and Fadda 2009). 
(Figure 1)
Thus, the stratum corneum represents 
the physical epidermal barrier against 
the percutaneous penetration of chem-
icals and microbes and is capable of 
withstanding mechanical forces. The final 
steps in keratinocytes differentiation are 
associated with profound changes in their 
structure, resulting in this into anucleated 
and flattened cells, called corneocytes. 
These are densely packed within the ex-
tracellular lipid matrix which is arranged 
in bilayers, often called “brick and mor-
tar” arrangement, where the protein rich 
corneocytes represent the bricks and the 
lipid matrix, the mortar, originally de-
scribed by Michaels et al. 1975 (Michaels, 
1. IntroductIon
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Figure 1. Layer of the skin
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Chandrasekaran, and Shaw 1975). (Figure 
3)
At the ultrastructural level, both the 
bricks and the mortar components of the 
paper-thin stratum corneum have incred-
ible structural and functional complexity, 
metabolic adaptations and ability for au-
topoesis (self-maintenance by constant 
renewal).
The protein envelop contributes to the 
biomechanical properties of the stratum 
corneum as a result of cross-linking of 
specialized cornified envelope structural 
proteins, including loricrin, involucrin and 
trichohyalin. The mortar lipids filling the 
tortuous pathway between the stacked 
corneocytes: a highly complex mixture of 
about 13 species of ceramides, choles-
terol, and free fatty acids, these provide 
the permeability barrier. Ceramides are 
approximately 50% of the total lipid mass 
and responsible of the lipid organization. 
Cholesterol (25%) improves the mixing of 
the different lipid compounds. The free 
fatty acids (10%) are mainly saturated 
with a chain length of 20 carbon atoms or 
stratum corneum
lipid bilayer
acid sphingomyelinase
β-glucocerebrosidase
phospholipase steroid sulfatase
lamellar body (containing hydrolytic 
enzymes and phospholipids, ceramides, 
glycosyl ceramides and sterols
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Figure 2. Schematic diagram of the 
epidermis.
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Figure 3: Barrier function of the 
epidermis
brick=corneocyte
mortar=Lipid (Membrane bilayers)
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more, with additional smaller fractions of 
oleic and linoleic acids.
The nucleated epidermis also contrib-
utes to the barrier through tight, gap and 
adherens junctions, as well as through 
desmosomes and cytoskeletal elements. 
During epidermal differentiation lipids 
are synthesized in the keratinocytes and 
extruded into the extracellular domains, 
where they form extracellular lipid-en-
riched layers. The cornified cell envelope, 
a tough protein⁄lipid polymer structure, 
resides below the cytoplasmic membrane 
on the exterior of the corneocytes. Cer-
amides A and B are covalently bound to 
cornified envelope proteins and form the 
backbone for the subsequent addition of 
free ceramides, free fatty acids and cho-
lesterol in the stratum corneum. Filaggrin 
is cross-linked to the cornified envelope 
and aggregates keratin filaments into 
macrofibrils.
Formation and maintenance of barrier 
function is influenced by cytokines, cyclic 
adenosine monophosphate and calcium. 
Changes in epidermal differentiation and 
lipid composition lead to a disturbed skin 
barrier, which allows the entry of environ-
mental allergens, immunological reaction 
and inflammation in atopic dermatitis. A 
disturbed skin barrier is important for the 
pathogenesis of contact dermatitis, ich-
thyosis, psoriasis and atopic dermatitis.
1.2. Vesicular carriers
The skin represents an ideal site for drug 
administration in terms of non-invasive 
application, offering some advantages 
over classical oral dosage forms, such as 
reduction of drug systemic toxicity, im-
provement of local activity and patient 
compliance.
Recently, it has become evident that the 
use of nanocarriers to deliver drugs to 
the skin increases penetration and per-
meation through the stratum corneum, 
but they can also be exploited to localize 
the drug upon topical treatment. Ration-
ally-designed nanocarriers may improve 
the therapeutic index of drugs, by mod-
ifying their pharmacokinetic and biodis-
tribution (Jadoul et al. 1999; Thomas and 
15
Finnin 2004)(Sinico and Fadda 2009).
Among the several nanosystems in the 
pharmaceutical panorama, phospholipid 
vesicles, namely liposomes, have been 
extensively studied (figure 4). Many stud-
ies show that skin deposition of phos-
pholid vesicles is affected by a number 
of factors, such as lipid composition, 
vesicle structure and the thermodynamic 
state of the lipid bilayer. Several authors 
have been showing that the modification 
of lipid vesicle composition can lead to 
elastic, deformable and/or soft vesicles 
that have superior ability to enhance 
dermal and transdermal drug delivery 
with respect to conventional liposomes. 
Therefore, a great deal of innovative li-
pid vesicles has been introduced, such 
as transfersomes and ethosomes, which 
are reported to have superior skin pen-
etration ability. thus enhancing drug bio-
availability and prolonging their efficacy, 
via non-invasive routes (Muzzalupo et al. 
2011; Sinico and Fadda 2009; Touitou et al. 
2000). 
1.2.1. Penetration enhancer containing 
vesicles (PEVs)
More recently, the group of Technologies 
of the University of Cagliari has been 
studying the delivery of drugs by new 
phospholipid vesicles, named Penetra-
tion Enhancer-containing Vesicles (PEVs), 
which are  liposomes containing in their 
composition a penetration enhancer mol-
ecule, capable of influencing vesicle per-
formances and transdermal drug delivery. 
(figure 5). Vesicles have been prepared 
following different methods, using sever-
al phospholipids and drugs, and various 
penetration enhancers differing in physic-
ochemical properties and mechanism of 
skin penetration enhancement. Effective 
and appropriate PEV formulations have 
been obtained with the aim of reaching 
an efficient delivery of different drugs 
(e.g. tretinoic acid, minoxidil, diclofenac 
and quercetin) to skin or subcutaneous 
tissue (Caddeo et al. 2012; Chessa et al. 
2011; Manconi et al. 2009; Manconi, Cad-
deo, et al. 2011; Manconi, Sinico, et al. 
1. IntroductIon
Figure 4:  Structure of phospholipid 
vesicles: liposomes.
Figure 5: Structure of PEVs
Hydrophilic drug molecules
Phospholipid bilayer
Lipid molecule
Hydrophobic tail
Hydrophilic head
Hydrophobic PE Hydrophilic PE
Lipophilic drug molecules
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2011; Mura et al. 2009, 2011).
In this framework, considerable attention 
has been devoted to studying  the ability 
of the PEVs to entrap anti-inflammatory 
drugs and to enhance their in vitro and 
in vivo efficacy in the local treatment of 
various inflammatory diseases. 
 
1.3. Inflammation
Inflammation is an essential protective 
process for preserving the integrity of 
organisms against physical, chemical 
infective and autoimmune causes. How-
ever, it is frequent that the inflammatory 
response to several insults erroneously 
leads to the damaging of normal tissues 
due to an overproduction of reactive 
oxygen species (ROS), nitric oxide (NO) 
and cytokines, such as tumor necrosis 
factor-alpha (TNF-ɑ) (Manconi, Caddeo, 
et al. 2011). 
Therapeutic treatments involve the care 
of symptoms by stopping the anti-in-
flammatory process and, if possible the 
native cause. Usually, inflammation is lo-
calized in a specific organ or apparatus, 
like skin, subcutaneous tissue, muscular 
or osteoarticular apparatus, and it can of-
ten become chronic (figure 6). Long-term 
systemic cures with steroidal or non-ste-
roidal anti-inflammatory drugs can cause 
the onset of several side effects and a low 
drug bioavailability at the site of action 
(Tavano, Muzzalupo, Trombino, et al. 2010). 
Cutaneous administration represents a 
valid alternative to systemic treatment 
of local inflamed skin or muscle. In par-
ticular, the nanoencapsulation of anti-in-
flammatory drugs can improve their local 
bioavailability and efficacy minimizing 
side effects. Among different nanocar-
riers, phospholipid lamellar vesicles are 
one of the most versatile systems for the 
improvement of skin penetration and 
permeation of drugs. Different anti-in-
flammatory drugs have been successful-
ly included within phospholipid vesicles 
(e.g., liposomes, transfersomes, and 
ethosomes) to efficiently enhance their 
transdermal delivery (Sinico and Fadda 
2009).
Diclofenac (DCF) is one of the most po-
1. IntroductIon
Figure 6: Representative histological 
sections of skin: A) inflamed skin and 
B) healthy skin.
A
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tent and commercially successful non-ste-
roidal anti-inflammatory drugs (NSAIDs), 
very often used in transdermal drug deliv-
ery. Due to several drawbacks when orally 
given, topical administration is preferable 
for diclofenac in long-term cures, such as 
treatment of local muscle inflammation, 
although the drug shows low skin perme-
ability. Different penetration enhancers 
have been employed to increase its per-
cutaneous absorption, as they reversibly 
reduce the skin barrier resistance (Mura et 
al. n.d.)(Mura et al. 2011).
Alternatively to conventional NSAIDs, 
natural and safe anti-inflammatory drugs, 
such as polyphenols, flavonoids and 
cumarins, are being proposed to be en-
capsulated in phospholipid vesicles and 
administered to the skin. Flavonoids are 
a group of naturally occurring polyphe-
nolic compounds that are found in most 
plants and are reported to have a signifi-
cant impact on the inflammatory process. 
Curcumin (CUR) and quercetin (QUE) are 
among the most widely distributed flavo-
noids, and have demonstrated to possess 
potent anti-oxidant, anti-inflammatory 
and anti-carcinogenic activities. They 
control the formation of proinflammato-
ry mediators, such as prostaglandins and 
leukotrienes. Curcumin has been shown 
to reduce edema in rats and to moder-
ately reduce the clinical symptoms in 
rheumatoid arthritis patients. Quercetin 
inhibits mast cell degranulation, release 
of histamine and also inhibits phospholi-
pase A2, cyclooxygenase and lipoxygen-
ase activity. Although previous studies 
suggest that both curcumin and querce-
tin have significant anti-inflammatory and 
anti-allergic properties, unfortunately 
the efficacy of these natural antioxidants 
is limited by low in vivo bioavailability, 
which limits their potential health bene-
fits (Scalia and Mezzena 2009)(Montenegro 
et al. 2007)(Vicentini et al. 2008)(Hjorth Tøn-
nesen et al. 1993; Subramanian et al. 1994) 
21
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2. AIM OF THE WORK
Topical drug delivery has gained incre-
ased importance for anti-inflammatory 
drug delivery and several methods have 
been proposed to improve drug locali-
zation into the skin and inflamed tissues 
in order to enhance drug bioavailability 
as well as to reduce systemic side effects. 
Among the several proposed methods, 
the use of nanoparticulate carries has 
shown a great deal of interest with dif-
ferent and new nanovesicular carriers 
introduced by different research teams. 
Moreover, the liposomal carriers have the 
capability to vehiculate drugs with low 
water solubility, to protect them from en-
vironment and also to improve cutaneous 
delivery of drugs with low skin permea-
bility.
Therefore, the purpose of the present 
study was to formulate new vesicular car-
riers to optimize the topical delivery of 
anti-inflammatory drugs:
- diclofenac sodium salt, 
- quercetin,
- curcumin. 
These drugs are characterized by diffe-
rent molecular structures and, this, diffe-
rent physico-chemical properties. 
In particular, diclofenac shows several 
drawbacks when orally given but its to-
pical delivery is limited by low skin per-
meability. Topical bioavailability of quer-
cetin is hindered by its poor solubility in 
aqueous media and low skin permeability 
while the poor hydro-soluble curcumin is 
also photosensible and instable. 
Therefore, their incorporation  into inno-
vative vesicles, PEVs, also containing a 
penetration enhancer could be a useful 
tool to improve their performance. There-
fore, in this study new PEVs, different for 
composition and/or lipid concentration, 
have been prepared using glycol pene-
tration enhancers to evaluate their aptitu-
de as topical carriers to efficiently deliver 
these drugs to the skin allowing the drug 
to reach therapeutic levels into inflamed 
fibroblasts. The formulations were fully 
characterized from the  physico-chemi-
cal and technological point of view while 
their properties as carriers were evalua-
ted by in vitro and in vivo experiments. 
24
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3. CLOSE - PACKED VESICLES FOR DICLOFENAC SKIN DELIVERY AND 
FIBROBLAST TARGETING
Published in Colloids and Surfaces B: Biointerfaces 111, 609-617, 2013 
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3.1. Introduction. 
Topical delivery of drugs has several ad-
vantages over other traditional routes of 
administration, including improved bio-
availability for drugs that suffer gastroin-
testinal environment and/or hepatic first 
effects. However, the barrier nature of the 
stratum corneum (SC) represents a signif-
icant obstacle for most drugs to be deliv-
ered into and through the skin using the 
classical dosage forms such as creams, 
ointments, and gels. To overcome the 
barrier properties of the SC and enhance 
drug transport across intact skin, several 
techniques have been developed (Jadoul 
et al. 1999; Sinico and Fadda 2009; Thomas 
and Finnin 2004). One of the approaches 
especially studied in the last decades is 
the use of lipid nanocarriers, such as in-
novative liposomal vesicles (Cosco et al. 
2008; Muzzalupo et al. 2011; Tavano, Muz-
zalupo, Cassano, et al. 2010). Introduction 
of these delivery systems in nanomedi-
cine has several advantages that include 
safety of the carrier, its capability to en-
hance drug delivery into/through the 
skin as well as to deliver the drug to its 
therapeutic target while reducing drug 
toxicity. Diclofenac (DCF), a phenyl ace-
tic acid derivative, is a potent member of 
the non-steroidal anti-inflammatory drugs 
(NSAIDs), frequently used for treatment 
of rheumatic disorders and other chronic 
inflammatory diseases. In chronic inflam-
mations, such as arthritis, fibroblasts are 
the source of anti-inflammatory mediators 
and contribute to disease persistence in a 
defined anatomical location. Fibroblasts 
show a disordered behavior that causes 
an excessive survival and accumulation 
of leukocytes within inflamed tissues 
(Manconi, Caddeo, et al. 2011). They are 
responsible for tissue injury and cartilage 
invasion in the presence of inflammatory 
infiltrates. Therefore, topical DCF delivery 
could be useful to reduce the drug sys-
temic toxicity while improving its local ef-
ficacy (Tavano, Muzzalupo, Trombino, et al. 
2010). The use of vesicular drug delivery 
systems, such as liposomes, niosomes, 
ethosomes, and transfersomes, may en-
capItolo 3_close - packed vesIcles for dIclofenac skIn delIvery and fIbroblast targetIng
30
phd program in scienze e tecnologie farmaceutiche -xxvi ciclo-
hance DCF delivery into and through 
the skin allowing the drug to reach ther-
apeutic levels into inflamed fibroblasts 
(Battaglia and Ryan 2005; Caddeo et al. 
2008; Manconi et al. 2003, 2005; Manconi, 
Sinico, et al. 2011). In previous works, we 
prepared and tested penetration enhanc-
er-containing vesicles (PEVs) as promising 
carriers for enhanced (trans)dermal de-
livery of diclofenac, in the form of either 
acid or sodium salt (C. Mura et al. 2011; 
Mura et al. 2009). In the present work, we 
propose concentrated and close-packed 
PEVs prepared using a high concentra-
tion (180 mg/ml) of a commercial lipid 
mixture containing phosphatidylcholine, 
phosphatidylethanolamine, fatty acids 
and triglycerides (Phospholipon®, P50) 
and Transcutol® P (Trc) mixed at different 
ratios (10, 20, 30%, v/v) with phosphate 
buffer solution (PBS, pH 7). Trc is a water 
miscible, atoxic, and biocompatible pen-
etration enhancer (PE). Diclofenac (DCF) 
was incorporated in transcutol-PEVs and 
conventional liposomes, which were used 
as control. Vesicles were characterized 
in term of morphology, size distribution, 
zeta potential, stability, lamellarity, and 
ability to promote ex vivo diclofenac skin 
delivery. The cytotoxic activity of empty 
and DCF-loaded vesicles was evaluated 
toward mouse 3T3 fibroblasts grown as 
confluent monolayer. Vesicle cell interac-
tions and cellular uptake were evaluated 
by fluorescence microscopy using ves-
icles labeled with the lipophilic marker 
1,2-dioleolyl-sn-glycero-3-phosphoetha-
nolamine-N-(lissamine rhodamine B sul-
fonyl) (Rho-PE) and loaded with the hy-
drophilic probe 5(6)-carboxyfluorescein 
(CF).
3.2. Materials and methods
3.2.1. Materials
Phospholipon® 50 (P50) containing phos-
phatidylcholine (45%), phosphatidyletha-
nolamine (10–18%), fatty acids (7%) and 
triglycerides (3%) was a gift from AVG 
S.r.l. (Milan, Italy); 1,2-dioleolyl-sn-glyce-
ro-3-phosphoethanolamine-N-(lissamine 
rhodamine B sulfonyl) (Rho-PE) was pur-
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chased by Lipoid GmbH (Ludwigshafen, 
Germany). 2-(2-Ethoxyethoxy)ethanol 
(Transcutol® P, Trc) was donated from 
Gattefossé (Saint Priest, France). Phos-
phate buffer solution (PBS, pH 7) was 
purchased from Carlo Erba Reagents 
(Rodano, Italy). DCF sodium, 5(6)-carbox-
yfluorescein (CF) and all the other prod-
ucts were purchased from Sigma–Aldrich 
(Milan, Italy). DCF free acid (DCF) was 
obtained by acidic precipitation from a 
solution of diclofenac sodium (Manconi 
et al. 2009; Manconi, Caddeo, et al. 2011).
3.2.2. Vesicle preparation
Liposomes and PEVs, were prepared 
weighing P50 (180 mg/ml), DCF (10 mg/
ml) and hydrating them with PBS or Trc/
PBS solution (10, 20 and 30%, v/v) to ob-
tain liposomes or PEVs. Dispersion was 
sonicated for 2 min with a Soniprep 150 
ultrasonic disintegrator (MSE Crowley, 
London, United Kingdom) (Caddeo et al. 
2008; Manconi et al. 2003, 2005).
Vesicle dispersions were purified from the 
non-incorporated drug by dialysis loading 
them into dialysis tubing (Spectra/Por® 
membranes, 3 nm pore size; Spectrum 
Laboratories Inc., Rancho Dominguez, 
CA, United States) and dialyzing against 
PBS at 5°C for 2 h. Drug loading efficien-
cy (E%), expressed as the percentage of 
the amount of drug initially used, was 
determined by high performance liquid 
chromatography (HPLC) after disruption 
of vesicles with Triton X-100. DCF content 
was quantified at 227 nm using a chroma-
tograph Alliance 2690 (Waters, Milano, 
Italy). The column was a Symmetry C18 
(3.5 μm, 4.6 mm × 100 mm, Waters, Mi-
lano, Italy). The mobile phase was a mix-
ture of 30% water and 70% acetonitrile 
(v/v), delivered at a flow rate of 0.5 ml/
min (Caddeo et al. 2008; Manconi et al. 
2003, 2005).
3.2.3. Vesicles characterization
Vesicles were characterized by Transmis-
sion Electron Microscopy (TEM) for vesi-
cle formation and morphology. Samples 
capItolo 3_close - packed vesIcles for dIclofenac skIn delIvery and fIbroblast targetIng
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were examined with a JEM-1010 (Jeol 
Europe, Paris, France) transmission elec-
tron microscope equipped with a digital 
camera MegaView III and Software “Anal-
ysis”, at an accelerating voltage of 80 kV. 
The average diameter and polydispersity 
index (P.I.) of the samples were deter-
mined by Photon Correlation Spectrosco-
py (PCS) using a Zetasizer nano (Malvern 
Instrument, Worcestershire, United King-
dom). Zeta potential was estimated using 
the Zetasizer nano by means of the M3-
PALS (Phase Analysis Light Scattering) 
technique. All the samples were analyzed 
24 h after their preparation. A stability 
study was performed by monitoring the 
vesicle average size and zeta potential 
over 90 days at 4 ± 2  C.
3.2.4. X-ray diffraction
Vesicle structure was studied by small and 
wide-angle X-ray scattering (SWAXS). 
SAXS and WAXS patterns were recorded 
simultaneously using a S3-MICRO SWAXS 
camera system (HECUS X-ray Systems, 
Graz, Austria). The working q-range was 
0.003–0.6 Å−1, where q = (4π sin θ)/λ 
is the modulus of the scattering wave 
vector, θ the scattering angle and λ the 
wavelength. The diffraction patterns were 
recorded at 25 C. All scattering curves 
were reproduced twice with subsequent 
calculation of the electron distance distri-
bution, and yielded identical results. For 
the figures, a representative curve was se-
lected, plotting the scattering intensity (I) 
as a function of the scattering vector (q). 
SAXS patterns were analyzed using the 
program GAP (Global Analysis Program) 
developed by Pabst (Battaglia and Ryan 
2005; Pabst et al. 2003). The analysis 
technique models the full q-range in the 
SAXS regime, including Bragg peaks and 
diffuse scattering. The GAP allows fitting 
the SAXS pattern of bilayer-based struc-
tures, i.e. vesicles and lamellar phases. 
From the analysis, the membrane thick-
ness was obtained through the definition 
dB = 2(zH + σH). zH derives from SAXS 
curve fitting with GAP, while σH was kept 
fixed at 3 Å.
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3.2.5. Rheological analysis
Steady shear tests and dynamic oscillato-
ry tests were performed with a controlled 
strain and stress rheometer (Kinexus pro, 
Malvern Instrument, Worcestershire, Unit-
ed Kingdom) equipped with an rSpace 
data acquisition software. Analyses were 
carried out using a double-gap concentric 
cylinder. The double-gap configuration is 
useful for low viscosity dispersions. Vis-
cometry experiments were conducted in 
a shear range of 0.01–10 Pa. All samples 
were subjected to an initial amplitude 
sweep to determine the linear viscoelas-
tic region where the values of the moduli 
are independent of the applied deforma-
tion. Subsequent frequency sweep tests 
were performed from 0.01 to 10 Hz, and 
at a shear stress of 0.5 Pa. The oscillatory 
parameters used to compare the viscoe-
lastic properties of the different disper-
sions were the storage modulus (G′) and 
the loss modulus (G″). All measurements 
were made in triplicate, at a constant 
temperature of 25 ± 2  C.
3.2.6. Ex vivo skin penetration and per-
meation studies
Experiments were performed non occlu-
sively by means of Franz diffusion cells 
(diffusion area of 0.785 cm2), using new 
born skin of Goland–Pietrain hybrid pigs 
(1.2 Kg), provided by a local slaughter-
house and used within 24 h after excision. 
Skin was kept at 4  C and, 12 h before the 
experiments, it was pre-equilibrated in 
PBS solution at 37 °C. Skin specimens (n 
= 6) were sandwiched securely between 
donor and receptor compartments of the 
Franz cells, with the stratum corneum (SC) 
side facing the donor compartment. The 
receptor compartment was filled with 5.5 
ml of PBS solution, which was continuous-
ly stirred and thermostated at 37 ± 1 °C 
to reach the physiological skin tempera-
ture (i.e. 32 ± 1 °C). 100 μl of the samples 
was placed onto the skin surface. At reg-
ular intervals (1, 2, 4, 6, 8 h) the receiving 
solution was withdrawn and analyzed by 
HPLC for drug content (as described in 
Section 2.2).
After 8 h, the skin surface of specimens 
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was washed and the SC was removed 
by stripping with adhesive tape Tesa AG 
(Hamburg, Germany). The epidermis was 
separated from the dermis with a surgi-
cal sterile scalpel. Tape strips, epidermis, 
and dermis were placed each in metha-
nol, sonicated to extract the drug, and 
then assayed for drug content by HPLC 
(see Section 2.2).
3.2.7. Cell cultures
Mouse 3T3 fibroblasts (ATCC collection) 
were grown as confluent monolayer at 37 
°C in phenol red-free Dulbecco’s Mod-
ified Eagle’s medium (DMEM) (Life Tec-
nologies Europe, Monza, Italy) with high 
glucose, supplemented with 10% (v/v) 
fetal bovine serum, penicillin (100 U/ml), 
and streptomycin (100 μg/ml) (Life Tech-
nologies Europe, Monza, Italy) in 5% CO2 
incubator at 37 °C.
3.2.8. Cell viability studies (MTT assay)
3T3 cells were plated into 24-well plates 
at a density of 5 × 104 cells/well. After 24 
h of incubation, 3T3 cells were treated for 
2, 4, 8, 24 and 48 h with empty vesicles 
or DCF-loaded vesicles or DCF solution 
(50 μl of formulation in 500 μl of medium). 
Cell viability was determined by the MTT 
[3(4,5-dimethylthiazolyl-2)-2,5-diphen-
yltetrazolium bromide] colorimetric assay. 
Briefly, 500 μl of MTT reagent (0.5 mg/
ml in PBS) was added to each well and 
after 2 h the formed formazan crystals 
were dissolved in DMSO. The reaction 
was spectrophotometrically measured at 
570 nm with a microplate reader (Synergy 
4, ReaderBioTek Instruments, AHSI S.P.A, 
Bernareggio, Italy). All experiments were 
repeated at least three times and in tripli-
cates. Results are shown as percent of cell 
viability in comparison with non-treated 
control cells (100% viability).
3.2.9. Cellular uptake of RhoPE labeled 
CF loaded vesicles
The cell interactions and cellular up-
take were investigated by fluorescence 
microscopy using vesicles labeled with 
a lipophilic fluorescent marker 1,2-di-
oleolyl-sn-glycero-3-phosphoethanola-
35
mine-N-(lissamine rhodamine B sulfonyl) 
(0.035 mg/ml; Rho-PE) and loaded with 
a hydrophilic fluorescent marker 5(6)-car-
boxyfluorescein (0.025 mg/ml; CF). 
Vesicles were purified from the non-en-
trapped markers by dialysis (see Section 
2.2). 3T3 cells were grown in 35 mm dish-
es and experiments were carried out two 
days after seeding when the cells became 
confluent and stopped dividing due to 
contact inhibition. Cells were incubated 
at 37 °C with RhoPE labeled CF loaded 
vesicles (50 μl of formulation in 500 μl 
of medium) for 2, 4 and 8 h. Before ob-
servations, cells were washed twice with 
DMEM to remove fluorescent vesicles 
and background fluorescence, and then 
loaded with 650 μl  nuclear stain Hoechst 
33258. The adopted filters allowed for 
a virtually complete separation of the 
emissions and the simultaneous observa-
tion of CF (green dye), Rho-PE (red) and 
Hoechst (blue) in live cells. In control ex-
periments, cells incubated with free CF 
at the same concentration of that used in 
the preparation of vesicle dispersions did 
not display any appreciable fluorescence, 
confirming that the free CF does not per-
meate cell plasma membranes.
3.2.10. Fluorescence microscopy and 
image analysis
Light microscopy observations were 
made using a Zeiss (Axioskop, Zeiss, 
Oberkochen, Germany) equipped with 
20× and 40×/0.75 and a HBO 50W L-2 
mercury lamp (Osram, Berlin, Germany). 
Twelve images were acquired with a CCD 
camera (QICAM, Q imaging, Canada). 
CF, Rho-PE and Hoechst 33258 fluores-
cence was observed with 470 ±20/ 535 
±40, 546±6/  620 ±60 and 360 ±20/ 460 
± 25 excitation/emission filters respec-
tively. For quantification of intracellular 
fluorescence intensity, acquired images 
were processed for background subtrac-
tion and a 3 × 3 median filter was applied 
in order to flatten noise variations. The 
value related to the pixel pointed by the 
mouse was recorded as fluorescence in-
tensity (arbitrary units). Digital images 
were analyzed and image alignments 
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Figure 1. Negative stain electron mi-
crographs of DCF-loaded vesicles 
before (a) and after few minutes of wa-
ter dilution (b) 10% Trc-PEVs, (c) 20% 
Trc-PEVs (d) 30% Trc-PEVs.
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were obtained with Image Pro Plus soft-
ware (Media Cybernetics, Silver Springs, 
MD). Calculations were made with Excel 
(Microsoft Co., Redmond, WA).
3.2.11. Statistical analysis of data
Data analysis was carried out with the 
software package R, version 2.10.1. Re-
sults are expressed as the mean ± stand-
ard deviation. Multiple comparisons of 
means (Tukey test) were used to sub-
stantiate statistical differences between 
groups, while Student’s t-test was used 
for comparison between two samples. 
Significance was tested at the 0.05 level 
of probability (p).
3.3. Results and discussion
3.3.1. Vesicles characterization
In previous studies, different penetra-
tion enhancers (PEs, transcutol, propylen 
glycol, labrasol and oramix) were used 
to prepare alternative phospholipid ves-
icles (PEVs) as carriers for (trans)dermal 
delivery of different model drugs (Man-
coni et al. 2003, 2009; Manconi, Caddeo, 
et al. 2011; Manconi, Sinico, et al. 2011; C. 
Mura et al. 2011; Mura et al. 2009). Results 
underlined PE capability of influencing 
vesicle physicochemical properties and 
enhancing (trans)dermal drug delivery. In 
the present work, new concentrated and 
interconnected P50-PEVs, containing in-
creasing amounts of Trc (10%, 20%, 30%), 
were tested ex vivo in comparison with 
P50-liposomes (control). P50 (180 mg/
ml) was used to prepare stable vesicles 
loading 10 mg/ml of DCF. This concen-
tration was needed to avoid drug precipi-
tation and vesicle instability. Moreover, all 
these highly lipid concentrated vesicles 
strongly interacted each other forming 
interconnected and densely packed ves-
icles mixed to other bilayered structures 
(Battaglia and Ryan 2005). However, 
when diluted in water or applied onto 
the skin, they are able to maintain their 
structure and size but, within minutes, 
convert to single vesicles as confirmed by 
TEM micrographs. As an example, Figure 
1a shows a TEM picture of 10% Trc-PEVs, 
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Table 1. Average size, polydispersity 
index (PI), zeta potential (ZP) of empty 
and DCF-loaded liposomes and PEVs, 
incorporation efficiency (E%) of DFC. 
Each value is the mean ±SD of at least 
four experimental determinations
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lIposomes
 Sample
lIposomes
10% trc-pevs
10% trc-pevs
20% trc-pevs
20% trc-pevs
30% trc-pevs
30% trc-pevs
empty
dcf
84 ± 7
Size (nm)
75 ± 9
0.22
PI
0.23
-49 ± 2
ZP (mV) E (%) DCF
-61 ± 3 -77 ± 4
109 ± 6
97 ± 3
0.21
0.20
-67 ± 3
-72 ± 5 -70 ± 5
253 ± 11
220 ± 15
0.27
0.25
-70 ± 3
-76 ± 2 -57 ± 4
136 ± 5
162 ± 9
0.16
0.18
-75 ± 4
-81 ± 4 -48 ± 6
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where close and interconnected multila-
mellar vesicles are clearly evident togeth-
er with lamellar ribbons. Upon dilution, 
all systems evolve to single multilamellar 
(Figure 1b and d, 10 and 30% Trc-PEVs, 
respectively) or unilamellar vesicles as 
shown in Figure 1c for 20% Trc-PEVs.
Results of vesicle characterization, in 
terms of mean size, polydispersity index 
(PI), and zeta potential values are shown in 
Table 1. For all formulations, vesicle mean 
size ranged from 75 to 253 nm with a fair-
ly narrow size distribution (PI 0.16–0.27). 
Results indicated that the particle diame-
ter was strongly affected by the presence 
of Trc but not by the drug. In fact, drug 
entrapment did not statistically change 
the average size of all vesicles, except 
for 20% Trc-PEVs, whose mean diameter 
statistically decreased in the presence of 
DCF. The Trc effect was more evident: 
PEVs were always larger than control li-
posomes, in particular 20% Trc-PEVs 
showed the highest average size. This is 
probably due to an increased hydration 
of the lipid membrane surface in the pres-
ence of Trc with a consequent modifica-
tion of bilayer swelling or Trc could have 
interpenetrated the lipid hydrocarbon 
chains causing a modification in packing 
assembly (McDaniel, McIntosh, and Simon 
1983). Vesicle surface charge primarily de-
pends on the lipid composition: the main 
P50 component is phosphatidylcholine, a 
zwitterionic compound that at pH 7.0 car-
ries a negative charge, as well as the fatty 
acids (7% in the P50-mixture). Therefore, 
a negative charge in all formulations was 
observed. The negative charge increased 
with the addition of Trc and DCF from −49 
mV for empty liposomes to −81 mV for 
DCF-loaded 30% Trc-PEVs. PEVs always 
showed a negative zeta potential value 
higher than that of control liposomes and 
empty vesicles. Control liposomes were 
able to incorporate DCF in good yields 
(77%), always higher than those of PEVs 
that showed a drug loading capacity (E%) 
that decreased when Trc increased, vary-
ing between 48% and 70% (Table 1).
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Figure. 2. (a) Small angle X-ray dif-
fraction (SAXS) patterns and maximum 
q value of scattering curve of DCF-lo-
aded liposomes and PEVs. (b) Storage 
(G′) and loss (G″) moduli against 
frequency of liposomes and PEVs.
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3.3.2. Small-angle X-ray scattering
Vesicle structure was confirmed by 
small-angle X-ray scattering (SAXS). SAXS 
scattering curves of intensity (I) versus 
wave vector (q) for control liposomes and 
PEVs are shown in Figure 2 (a). Liposome 
curve presented a diffuse scattering, with 
a weak (q~0.117 Å−1), no sharp but dis-
tinctive single peak indicating the pres-
ence of unilamellar vesicle with bilayer 
thickness of (dB) 47.4 Å. 10% Trc-PEVs 
displayed a sharp diffraction first order 
peak, at higher q value (0.125 Å−1) and 
a lower second order peak indicative of 
multilamellar structures. Increasing Trc 
percentage to 20%, the peak shifted to 
lower q values (0.121 Å−1) but became 
wider and its intensity decreased be-
cause the amount of lamellar structures 
decreased. The signal of 30% Trc-PEVs 
(fully hydrated lipid membrane) showed 
a narrow peak and a lower second or-
der peak characteristic of a multilamellar 
structure (q 0.125 Å−1), distinctly sharp-
er than those from the 10% Trc-PEV dis-
persion, thus, indicating a larger size of 
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3.3.3. Rheological analysis
Rheological properties of samples de-
pend on strength of particle–particle 
interactions occurring at supramolecu-
lar level and on vesicle deformability at 
intramolecular level. These, in turns, are 
affected by the microstructure of the 
lamellar vesicles. The effect of Trc con-
centration on the apparent viscosity of 
vesicle dispersions was first examined. In 
the plot of shear rate versus shear stress 
(data not shown), behavior of control li-
posomes and PEVs (Trc 10% and 30%) 
is like Newtonian fluids: the shear rate 
linearly increased when the shear stress 
increased and the constant of proportion-
ality was the apparent viscosity (=shear 
stress/shear rate). Vesicle viscosity was 
higher than that of water (1 mPa s): ap-
proximately 5, 19, and 13 mPa s for con-
trol liposomes, 10% and 30% Trc-PEVs, 
respectively, and even higher than that of 
Trc/PBS solution (30%), which was about 
3 mPa s. Viscosity increase is due to the 
existence of interconnected and densely 
packed lamellar vesicles that fill up a dif-
the lamellar domains in this dispersion 
(Battaglia and Ryan 2005). Therefore, the 
tree different Trc concentrations led to a 
different P50 organization. 10% and 30% 
Trc produced multilamellar vesicles: 10% 
Trc addition allowed a structure change in 
comparison with control liposomes (from 
uni- to multi-lamellar) but not in bilayer 
thickness (dB 47.0 Å). Moreover, only a 
slight increase in vesicle diameter was ob-
tained because Trc improved hydration of 
the lipid membrane surface with a con-
sequent modification of the inter-lamellar 
long-range forces and lamellarity; 20% 
Trc interpenetrated the lipid hydrocarbon 
chains causing a modification in packing 
assembly and bilayer thickness (dB 46.4 
Å) and, thus, establishing a change of 
bilayer curvature with a strong improve-
ment of size; 30% Trc addition slightly 
affected bilayer thickness (dB 47.0 Å) 
and also the hydration of the lipid mem-
brane surface leading to a simultaneous 
increase of lamellarity and size (in com-
parison with control liposomes).
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ferent hydrodynamic volume fraction. Us-
ing Trc 20%, the viscosity of PEVs drasti-
cally increased, reaching higher orders of 
magnitude (53 mPa s) and showing a plas-
tic behavior with yield-stress values (data 
not shown). Additionally, the storage (G′) 
and the loss (G″) moduli of all samples 
were determined by oscillating rheolog-
ical measurements (Fig. 2b). The oscilla-
tory experiments emphasize a change of 
the viscoelastic behavior in the presence 
of 20% Trc in the vesicle dispersion. Con-
trol liposomes and 10% and 30% Trc-PE-
Vs showed the same rheological behavior 
of water, a purely viscous fluid: loss mod-
ulus was higher than storage modulus but 
they were more viscous than water due 
to their densely packed vesicles. On the 
contrary, 20% Trc-PEVs showed an inver-
sion of behavior where the storage mod-
ulus predominated over the loss modulus 
and both moduli were higher than those 
of other vesicles. Therefore, the system 
behaves like a soft gel. Presumably, this 
indicates that control liposomes, 10% 
and 30% Trc-PEVs were densely packed 
small (75–150 nm) uni- or multi-lamellar 
vesicles occupying a low volume fraction 
while Trc 20% PEVs were densely packed 
and strongly interconnected larger unila-
mellar (253 nm) vesicles with an increased 
volume fraction (Chessa et al. 2011). This 
change in the microstructure induced a 
modification at the supramolecular lev-
el: large and multilamellar vesicles (high 
volume fraction) and high lipid concentra-
tion (densely packed vesicles) produced a 
reduction of free water between vesicles 
and an increased strength of particle–par-
ticle interactions, and, as a consequence, 
the system became elastic with a yield 
value.
3.3.4. Ex vivo permeation studies
The skin penetration ability of vesi-
cle-loaded DCF was evaluated by ex 
vivo experiments through new born pig 
skin. The amount of drug accumulated 
into stratum corneum, epidermis and 
dermis is expressed as the percentage 
of the drug applied onto the skin (Figure 
3 (a)). Ex vivo (trans)dermal experiments 
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lipids, and a fast release of the entrapped 
drug. This, free from the carrier, can per-
meate rapidly through the disordered 
and fluidized intercellular skin lipids.
To have an estimation of the main target 
of the topically applied drug by using 
PEVs, it is interesting to compare the ratio 
of DCF accumulated into and permeat-
ed through the whole skin, which gives a 
dimensionless number for the quantifica-
tion of the Local Accumulation Efficiency 
(LAC) of the formulations (Figure 3(a)). 
The highest LAC value was obtained from 
10% and 20% Trc-PEVs (LAC =9) that 
both showed a value 3-fold higher than 
that of control liposomes (LAC = 3). Over-
all results (LAC, drug accumulation and 
permeation values) suggest an important 
role of PEVs in delivering DCF into the 
skin where they form a depot from which 
the drug can be released and diffuse to 
the deeper tissues until fibroblast, the tar-
get of inflammation treatment.
3.3.5. Toxicity studies on 3T3 cells
The toxicity of control liposomes and 
showed an improved skin deposition of 
DCF when PEVs were used, mostly 10% 
and 20% Trc-PEVs that enhanced drug 
deposition two times more than con-
ventional liposomes reaching 16–17% of 
drug accumulated into the whole skin. 
Using 30% Trc-PEVs, DCF skin deposition 
was lower (12%) than that of other Trc-PE-
Vs, as previously found for DCF loaded 
P90-PEVs (6). Cumulative amounts of 
permeated drug (μg/cm2) were calculat-
ed and plotted against time (Figure 3 (b)). 
The flux (J) was established as the slope 
of the linear portion of the plot (Figure 
3(b)). The highest transdermal flux was 
obtained with control liposomes, i.e. con-
ventional vesicles that are recognized to 
simply act as penetration enhancer and 
not as true carriers (Sinico and Fadda 
2009). This result can be due to the uni-
lamellar structure and small size of these 
vesicles that lead to an increased vesicle/
skin interface, thus, favoring interaction 
with the outermost skin layer followed by 
the vesicle fusion, a consequent mixing of 
liposomal bilayers with intercellular skin 
Figure 3. (a) Amount of DCF (%) accumu-
lated in stratum corneum (SC), epidermis, 
dermis and in receptor compartment after 
8-h treatment with control liposomes or 
PEVs; Local Accumulation Capacity (LAC) 
value was drug accumulated into the skin/
drug delivered through the skin ratio. (b) 
Diffusion of DCF against time from control 
liposomes or PEVs. J was the transdermal 
flux (μg/cm2/h). Data represent the mean 
± standard deviation of at least six experi-
mental determinations.
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Figure 4. In vitro cytotoxic effect of 
empty (a) and DCF-loaded liposomes 
and Trc-PEVs (b) on 3T3 cells at diffe-
rent coincubation times. 
*p < 0.05, **p < 0.001 in comparison 
with untreated cells (100% viability).
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in particular from 8 h (44% mortality) to 48 
h (66% mortality), while in the same pe-
riod, DCF-loading control liposomes and 
10% PEVs significantly improved cell via-
bility, demonstrating a toxicity similar to 
that of the corresponding empty vesicles. 
On the contrary, from 8 h exposition time, 
20% and 30% Trc-PEVs showed a high-
er toxic effect, which further increased 
at 24–48 h. However, it is important to 
highlight that DCF loaded vesicles were 
always less toxic than the control solu-
tion at the same exposition time and, 
consequently, results demonstrated that 
vesicles are able to reduce drug toxici-
ty. Moreover, up to 48 h, DCF control li-
posomes and 10% Trc-PEVs showed the 
same statistical cell mortality value of the 
corresponding empty vesicles (26 and 
44% mortality, respectively), whereas us-
ing DCF loaded 20% and 30% Trc-PEVs 
the mortality slightly increased at 24 h 
and especially at 48 h, probably due to 
the simultaneous presence of the drug 
and Trc at higher concentrations (>10%).
PEVs against mouse 3T3 fibroblasts was 
evaluated in vitro according to the MTT 
assay (which measures levels of metabol-
ically active mitochondrial dehydroge-
nase enzymes). Survival of 3T3 fibroblast 
was assayed in vitro after incubation with 
empty and DCF-loaded control lipos-
omes and PEVs at different incubation 
time (2-4-8-24-48 h). As shown in Figure 
4(a), all empty vesicles (control liposomes 
and PEVs) did not show any significant 
cytotoxic activity in the first 4 h of incu-
bation (less than 20% mortality) com-
pared to untreated control cells (100% 
viability). At higher incubation times (8, 
24, 48 h), toxicity of control liposomes 
remained almost constant (~24% mor-
tality) whereas using PEVs especially 20 
and 30% Trc-PEVs, viability was reduced. 
Figure 4(b) shows results of the toxicity 
study of DCF-loaded vesicles compared 
to DCF free solution. At 2 and 4 h expo-
sition time, both vesicles and solution did 
not show any important toxicity (less than 
20% mortality).
DCF solution had the highest citotoxicity 
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incubated with control liposomes, 10% 
and 30% Trc PEVs displayed a compara-
ble intracellular fluorescence pattern: a 
punctate fluorescence of the Rho-PE in 
all cytoplasm and a diffuse fluorescence 
of CF mostly localized in the perinuclear 
area were detected (Figure 5), suggesting 
a vesicle internalization by Golgi-endoso-
mal compartment followed by release of 
the hydrophilic probe.
In particular, in the case of 3T3 living cells 
coincubated with 10% Trc PEVs intracellu-
lar Rho-PE-red fluorescence appears at all 
tested time points (especially at 4 and 8 h) 
and show a punctate pattern localized in 
the perinuclear area (data not shown). CF 
shows a diffuse green fluorescence very 
similar at all exposition time. As an exam-
ple, Figure 5 shows 30% Trc PEVs-treated 
cells, where the highest liposomal inter-
nalization was observed at all time but, 
simultaneously, the accumulation of the 
Rho-PE fluorescence was quite different 
from cell to cell. Indeed, some cells were 
full of cytoplasmic red fluorescence while 
other ones appeared almost empty, thus, 
3.3.6. Uptake studies on 3T3 cells
Vesicle uptake by 3T3 fibroblasts was 
investigated using double fluorescently 
labeled vesicles, which were loaded with 
a membrane marker (Rho-PE) and a hy-
drophilic fluorescent probe (CF). CF was 
chosen as marker of the liposome con-
tent since it is a membrane impermeable 
probe especially used for investigating 
membrane integrity and permeability 
(Lee et al. 1998; Manconi et al. 2007). When 
the cells reached a confluence, they were 
incubated for 2, 4 and 8 h with the dou-
ble fluorescently labeled vesicles, used at 
the same concentration tested for toxici-
ty studies (50 μl of formulation in 500 μl 
of medium), and imaged immediately by 
fluorescence microscopy after replacing 
the medium with fresh particle-free me-
dium in combination with the Hoechst 
33258, a blue fluorescent dye used for 
counterstaining the nucleus. Both control 
liposomes and PEVs were internalized by 
the 3T3 living cells as confirmed by the 
appearance of intense intracellular fluo-
rescence after 2 h of coincubation. Cells 
Figure 5. Images of 3T3 fibroblasts 
incubated for 2, 4 and 8 h with Rho-PE 
labeled and CF loaded 30% Trc-PEVs. 
The localization and intensity of dyes 
are displayed in red for Rho-PE , in 
green for CF , and in bleu for Hoechst. 
Bar = 20 μm. 
Rho-PE-labelled
2h
4h
8h
CF-loaded
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of 10% and 30% Trc PEVs was confirmed 
by the results of quantification of intra-
cellular Rho-PE fluorescence intensity. A 
statistical significant increase of red flu-
orescent intensity was observed in these 
formulations when compared to control 
liposomes (Figure 7a). The variability 
in cell uptake of 30% Trc PEVs was also 
confirmed by the SD values. The higher 
Rho-PE fluorescence intensity in 10% and 
30% Trc PEVs was not accompanied by a 
proportional fluorescence intensity of CF. 
In fact, Trc-PEVs treated cells displayed 
the same CF content in comparison with 
control liposomes, probably because CF 
loading capacity of Trc-PEVs decreased 
as Trc concentration increased. Indeed, 
CF entrapment efficiency diminished ac-
cording the following rank: liposomes (47 
± 6%) > 10%Trc PEVs (39 ± 5%) > 20% Trc 
PEVs (34 ± 4%)> 30% Trc PEVs (29 ± 5%). 
Finally, 20% Trc-PEVs showed Rho-PE 
and CF fluorescence values equal o mi-
nor than those of control liposomes due 
to the formation of vesicle aggregates on 
the membrane surface of the cells.
suggesting a great variability in cell up-
take (Figure 5 C). Conversely, the fluo-
rescence pattern in cells incubated with 
20% Trc PEVs (Figure 6) was very differ-
ent. Indeed, these vesicles were strong-
ly bound together to form a gel-like su-
pramolecular system making fluorescent 
aggregates that, in spite of the extensive 
washing with the culture medium, stayed 
attached to the plasma membrane sur-
face. In composite color images these 
vesicle aggregates can be clearly identi-
fied as very fluorescent yellow bodies re-
sulting from the co-localization of the two 
probes (Figure. 6b and c). Therefore, im-
ages suggest that these large aggregates 
could not be readily taken up by the cells 
because of their size but they stayed in-
tact adhering on the cell surface. Howev-
er, focusing on cell nucleus, a diffuse red 
and green perinuclear fluorescence can 
be detected (Figure 6d and f), thus con-
firming that a partial internalization had 
taken place also with 20%Trc PEVs, as es-
tablished by fluorescence data (Figure 7a 
and b). The increased cytoplasmic uptake 
Figure 6. Overlay of phase contrast 
and fluorescence image of cells 
exposed to 30% Trc-PEVs (a) and 20% 
Trc-PEVs (b). Rho-PE and CF loaded 
20% Trc-PEVs made fluorescent 
aggregates that appear as fluorescent 
yellow spots attached to the plasma 
membrane in the composite color 
image (c). Images of Rho-PE (d), CF (e) 
and merged (f) fluorescence of a cell 
focused on the nucleus. Bar = 20 μm. 
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Figure 7. Rho-PE (a) and CF (b) 
fluorescence values inside the cells. 
Number of measurements: n = 390, 
bars represent means ± standard 
deviation.
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3.4. Conclusion
This work has shown that the studied 
concentrated and densely packed Trc 
containing vesicles are good candidates 
for topical drug delivery. Indeed, these 
new nanocarriers are able to form a gel-
like interconnected vesicular dispersion 
that is characterized of a viscosity higher 
than that of water. Moreover, as the for-
mulation is topically applied, the expanse 
structure of the system evolves to single, 
small vesicles that carry the drug into and 
through the skin favoring its cutaneous 
deposition and, thus, interaction with 
fibroblasts. In vitro study with cells, per-
formed by using vesicles co-labeled with 
lipophilic and hydrophilic markers, has 
also proved that these high lipids concen-
trated PEVs are capable of being internal-
ized by the 3T3 fibroblasts. The vesicular 
carrier has also been demonstrated to re-
duce the in vitro drug toxicity. Therefore, 
the outcomes of the present investigation 
suggest these new transcutol containing 
close packed vesicles are good candi-
dates for improving DCF dermal delivery.
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and glycol IntercalatIon on structural assembly of phospholIpId lamellar vesIcles. 
4.1. Introduction
Several studies have been carried out 
to explore the interactions of drug or 
other components with lamellar vesicles 
and their effects on the bilayer structure 
(Kranenburg, Vlaar, and Smit 2004; Pign-
atello, Intravaia, and Puglisi 2006; Rosser, 
Lu, and Dea 1999). Any small molecules 
might cause bilayer packing alteration 
and among these chemicals, aliphatic 
alcohols are the best known and studied 
(Adachi et al. 1995; Kranenburg et al. 2004; 
Löbbecke and Cevc 1995). In particular, a 
large number of studies have been fo-
cused on ethanol effects in phospholi-
pid vesicles (Celia et al. 2009; Touitou et 
al. 2000). Results suggested that ethanol 
plays a significant role in the arrange-
ments of phospholipids on the bilayer, 
changing the acyl chain orientation inside 
the lamellar structure and usually forming 
an interdigitated structure (Adachi et al. 
1995; Komatsu and Okada 1995). Thanks 
to this, ethanol forms soft and fluid lamel-
lar vesicles able to improve skin delivery 
of several drugs. Alternatively to ethanol, 
others water miscible cosolvents such as 
isopropyl alcohol and propylene glycol 
(PG), have been used as additive of vesi-
cle bilayer to make innovative phospho-
lipid vesicles able to facilitate drug deli-
very, especially skin delivery (Caddeo et 
al. 2012; Chessa et al. 2011; Elmoslemany 
et al. 2012; Elsayed et al. 2007; Manconi, 
Caddeo, et al. 2011). However, the inte-
ractions involved among drug, water, 
cosolvent and phospholipid and the pos-
sible rearrangements that take place into 
bilayer were not deeply investigated. We 
recently reported the effect of diethylene 
glycol monoethyl ether (Transcutol®, Trc) 
and propylene glycol on self-assembling 
and rheological properties of phosphati-
dylcholine lamellar vesicles and we found 
that 10–20% of glycols allowed the for-
mation of vesicles with the more suitable 
and stable features (Manconi et al. 2012).
Here, the interactions between hydroge-
nated phosphatidylcholine bilayer vesi-
cles and the two glycols, differing in their 
structure, have been extensively studied. 
In particular, the effective glycol ability 
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ning the information obtained by diffe-
rential scanning calorimetry (DSC), small- 
and wide-angle diffraction signals (SAXS) 
and rheology studies. These techniques 
permitted to build a detailed picture of 
intra- and inter-vesicle assembly.
4.2. Materials and methods
4.2.1. Materials
Hydrogenated soy phosphatidylcholine 
(Phospholipon® 90H, P90H) was kindly 
supplied by AVG S.r.l. (Milan, Italy) and 
Lipoid GmbH (Ludwigshafen, Germany). 
Diethylene glycol monoethyl ether (Tran-
scutol® P, Trc) was kindly provided by 
Gattefossè (Saint Priest, France). Pho-
sphate buffer solution (PBS, pH 7) was 
purchased from Carlo Erba Reagents (Mi-
lan, Italy). Diclofenac sodium salt (DCF-
Na), cholesterol (Chol), and propylene 
glycol (PG) were purchased from Sigma–
Aldrich (Milan, Italy).
4.2.2. Vesicle preparation
Liposomes were prepared by using P90H 
to perturb phospholipid vesicle bilayer 
and the simultaneous effect of diclofenac 
sodium salt, were evaluated. This potent 
antinflammatory drug is commercially 
available in semisolid preparations for to-
pical application (Escribano et al. 2003). In 
this work it was used as model drug able 
to perturb phospholipid bilayer structu-
re, thanks to its amphiphilic properties 
(Schreier, Malheiros, and de Paula 2000)
(Lopes et al. 2004; Manconi et al. 2009; 
Manconi, Caddeo, et al. 2011).
The aim of the current study was to impro-
ve the knowledge of drug–glycol–pho-
spholipid-interactions and their effects in 
lamellar vesicle aptitude as topical carrier. 
The simultaneous addition of diclofenac 
sodium salt and a hydrophilic glycol (Trc 
or PG) to phospholipid dispersion led to 
the formation of a vesicle structure with 
a complex intervesicle architecture. The-
se important structural rearrangements 
were disclosed by a change on physical 
state from liquid to high viscous liquid or 
soft-solid like. The effects, at molecular 
level, have been monitored by combi-
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(60 mg/ml), Chol (2 mg/ml), DCFNa (5 and 
10 mg/ml) and PBS. PEVs were obtained 
using the same lipid phase (P90H, Chol), 
DCFNa (5 and 10.mg/ml) and a mixture 
of Trc/PBS or PG/PBS (5, 10, 20%, v/v) as 
water phase (Table 1). All components 
were weighted in a glass flask, hydrated 
with the water phase, and finally sonica-
ted (5 s on and 2 s off, 30 cycles; 14 μm 
of probe amplitude) with a high intensity 
ultrasonic disintegrator (Soniprep 150, 
MSE Crowley, London, United Kingdom) 
(Madrigal-Carballo et al. 2008; Manconi 
et al. 2003). Each formulation was puri-
fied from the non-encapsulated drug by 
dialysis. Samples were loaded into dialy-
sis tubing (Spectra/Por® membranes: 
12–14 kDa MW cut-off, 3 nm pore size; 
Spectrum Laboratories Inc., DG Breda, 
The Netherlands) and dialysed against 
PBS (liposomes) or appropriate glycol/
PBS (PEVs) mixtures for 2 h at 5 °C, to 
allow the dissolution and removal of the 
non-encapsulated drug and non-aggre-
gated phospolipids.
4.2.3. Vesicle characterization
Vesicle formation and morphology were 
assessed by cryo transmission electron 
microscopy (cryo-TEM) analysis. A thin 
aqueous film was formed by placing a 5 
μl sample drop on a glow-discharged ho-
ley carbon grid and then blotting the grid 
against filter paper. The resulting thin fil-
ms spanning the grid holes were vitrified 
by plunging the grid (kept at 100% humi-
dity and room temperature) into ethane, 
which was maintained at its melting point 
with liquid nitrogen, using a Vitrobot (FEI 
Company, Eindhoven, The Netherlands). 
The vitreous films were transferred to a 
Tecnai F20 TEM (FEI Company) using a 
Gatan cryotransfer (Gatan, Pleasanton, 
CA), and the samples were observed in 
a low dose mode. Images were acquired 
at 200 kV at a temperature between 170 
and 175  C, using low-dose imaging con-
ditions not exceeding 20 e−/Å2, with a 
CCD Eagle camera (FEI Company).
The average diameter and polydispersi-
ty index (PI), as a measure of the width 
of the size distribution of the samples, 
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were determined by Photon Correlation 
Spectroscopy using a Zetasizer nano-ZS 
(Malvern Instruments, Worcestershire 
United Kingdom). Samples were back-
scattered by a helium–neon laser (633 
nm) at an angle of 173° and a constant 
temperature of 25 °C. Zeta potential was 
estimated using the Zetasizer nano-ZS 
by means of the M3-PALS (Mixed Mode 
Measurement-Phase Analysis Light Scat-
tering) technique, which measures the 
particle electrophoretic mobility in a ther-
mostated cell. Each sample (10 μl) was 
diluted with 10 ml of PBS or the appro-
priate glycol/PBS mixture before analysis.
Drug entrapment efficiency (EE%), 
expressed as the percentage of the drug 
amount after dialysis versus that initially 
used, was determined by high perfor-
mance liquid chromatography (HPLC) 
after disruption of vesicles with metha-
nol (1:1000 dilution). Diclofenac sodium 
content was quantified at 227 nm using 
a chromatograph Alliance 2690 (Waters, 
Milan, Italy) equipped with a column 
Symmetry C18 (3.5 mm, 4.6 100 mm, Wa-
ters). The mobile phase was a mixture of 
water/acetonitrile (30/70, v/v), delivered 
at a flow rate of 0.5 ml/min (6).
The lipid content of dispersions was de-
termined by the Stewart (1980) (Stewart 
1980) assay. Briefly, an aliquot of liposo-
mes or PEV dispersions was added to a 
biphasic mixture of aqueous ammonium 
ferrithiocyanate solution (0.1 N) and chlo-
roform. The concentration of P90H was 
obtained by measuring absorbance at 
485 nm of the organic solution. The ag-
gregation efficiency (AE%) represented 
the effective amount of aggregated pho-
spholipids (after dialysis) expressed as the 
percentage of the initially used amount.
4.2.4. Vesicle stability
The vesicle stability was assessed by 
monitoring the vesicle average size and 
zeta potential over 90 days at 4 ± 1 ˚C. 
Drug release from the vesicles during the 
storage was evaluated by measuring the 
liposomes encapsulation efficiency over 
90 days.
Table 1. Acronyms, composition and 
physical state of liposomes and PEVs. 
Vesicles appeared as liquid, high 
viscous liquid (HV liquid) or soft solid.
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 Sample
 Empty liposomes
5DCF liposomes
5DCF 5Trc-PEVs
5DCF 10Trc-PEVs
5DCF 20Trc-PEVs
5DCF 5PG-PEVs
5DCF 10PG-PEVs
5DCF 20PG-PEVs
10DCF liposomes
 Physical state
 Liquid
 Liquid
 Liquid
HV Liquid
Soft solid
 Liquid
 HV Liquid
 Soft solid
Liquid
 HV Liquid
 Soft solid
Soft solid
 HV Liquid
 HV Liquid
 Soft solid
P90H
(mg/ml)
60
60
60
60
60
60
60
60
60
60
60
60
60
60
60
Chol
(mg/ml)
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
DCFNa
(mg/ml)
0
5
5
5
5
5
5
5
10
10
10
10
10
10
10
Trc
(% v/v)
0
0
5
10
20
0
0
0
0
5
10
20
0
0
0
PG
(% v/v)
0
0
0
0
0
5
10
20
0
0
0
0
5
10
10
PBS
(% v/v)
100
100
95
90
80
95
90
80
100
95
90
80
95
90
90
10DCF 5Trc-PEVs
10DCF 10Trc-PEVs
10DCF 20Trc-PEVs
10DCF 5PG-PEVs
10DCF 10PG-PEVs
10DCF 20PG-PEVs
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4.2.5. Differential scanning calorimetry 
analysis
DSC studies were performed using a DSC 
Mettler Toledo model 821e (Mettler To-
ledo International Inc., Barcelona, Spain). 
The samples were scanned in a sealed 
aluminum pans under nitrogen atmo-
sphere. DSC thermograms were scanned 
in the first heating run at a constant rate 
of 10 °C/min and a temperature range of 
0–80 °C.
 
4.2.6. X-ray diffraction
Vesicle structure of liposomes and PEVs 
was probed by small- and wide-angle 
X-ray scattering (SWAXS). SAXS and 
WAXS patterns were recorded simultane-
ously using two linear, one-dimensional, 
position-sensitive detectors (PSD 50 M; 
Hecus X-Ray Systems) containing 1024 
channels of width 54.0 μm. Cu Kα radia-
tion of wavelength 1.542 Å was provided 
by a GeniX X-ray generator, operating at 
50 kV and 1 mA.
The working q-range were 0.003–0.6 Å−1 
for SAXS and 1.3–1.9 Å−1 for WAXS, 
where q = (4π sin θ)/λ is the modulus of 
the scattering wave vector, θ the scat-
tering angle and λ the wavelength. All 
scattering curves, recorded at 25 °C, 
were reproduced twice with subsequent 
calculation of the electron distance distri-
bution, and yielded identical results. For 
the figures, a representative curve was se-
lected, plotting the scattering intensity (I) 
as a function of the scattering vector (q). 
The calibration of the q-scale was perfor-
med by measuring silver behenate in the 
SAXS range and p-bromo-benzoic-acid in 
the WAXS range.
SAXS patterns were analyzed in terms of 
a global model using the program GAP 
(Global Analysis Program) developed by 
Pabst (Pabst et al. 2000, 2003). The analy-
sis technique models the full q-range in 
the SAXS regime, including Bragg peaks 
and diffuse scattering. By this procedure, 
relevant structural parameters, as well as 
the distribution of electron density in the 
polar and apolar regions of membranes, 
were obtained. The GAP allows fitting the 
SAXS pattern of bilayer-based structures, 
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i.e. vesicles and lamellar phases. From 
the analysis, the membrane thickness 
was obtained through the definition dB = 
2 (zH + 2σH). zH and σH, obtained from 
SAXS curve fitting with GAP, represent 
the head group amplitude and its distan-
ce to the bilayer center the methyl termi-
nus or lipid half extend respectively.
4.2.7. Rheological studies
Rheological measurements were carried 
out at 25 ± 1 °C, using a Kinexus rota-
tional rheometer (Malvern Instruments, 
Worcestershire, United Kingdom) equip-
ped with data acquisition and elaboration 
software rSpace; a cone-plate geometry 
(CP1/60) was used. Before each analysis, a 
thin layer of silicon oil (Dimethicone, RFE/
Ph. Eur.) was laid on the free surface of 
the sample to prevent water evaporation. 
Frequency sweep tests were performed 
in the range 0.01–10 Hz and a shear stress 
of 0.1 Pa was used. Mechanical spectra 
of the storage (G′) and loss (G″) moduli 
were registered in the above mentioned 
frequency range and G′ at 1 Hz was used 
to characterize the viscoelastic properties 
of the different dispersions. Before fre-
quency sweep experiments, amplitude 
sweep experiments were carried out for 
each sample to determine the linear vi-
scoelastic region where the values of the 
moduli are independent by the applied 
deformation. Steady shear experiments 
were performed in the range 0.01–20 Pa. 
Viscosity at 1 s−1 was used to characteri-
ze the flow properties of different disper-
sions. All measurements were carried out 
in triplicate.
4.2.8. Statistical analysis of data
Data analysis was carried out with the 
software package R, version 2.10.1. Re-
sults are expressed as the mean ± stan-
dard deviation. Multiple comparisons of 
means (Tukey’s test) were used to sub-
stantiate statistical differences between 
groups, while Student’s t-test was used 
for comparison between two samples. Si-
gnificance was tested using at least 0.05 
level of probability (p).
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4.3. Results and discussion
4.3.1. Liposome and PEV preparation 
and characterization
In the present work Trc or PG were mixed 
in the water phase at different concentra-
tions (5, 10, 20%, v/v) to obtain innova-
tive P90H phospholipid vesicles termed 
PEVs (penetration enhancer containing 
vesicles) to distinguish them from con-
ventional liposomes. DCFNa, widely used 
for the treatment of local and chronic in-
flammatory disease, was used as a mo-
del drug at two different concentrations 
(5 and 10 mg/ml) in order to investigate 
the ability of this amphiphilic molecule to 
interact with phospholipids and to cau-
se modifications of the vesicles structu-
re (Lopes et al. 2004; Tavano, Muzzalupo, 
Trombino, et al. 2010). In order to carry 
out an appropriate comparison, empty 
and DCFNa loaded liposomes were also 
prepared and characterized. Acronyms, 
composition and physical state of sam-
ples are summarized in Table 1. At vi-
sual inspection, important differences 
on sample physical state were evident: 
liposomes were liquid while vesicles con-
taining low glycol concentrations appea-
red highly viscous liquid probably due to 
different and concomitant effects such as 
the use of a hydrogenated phospholipid 
at high concentration and the simultane-
ous presence of drug and glycols. Final-
ly, 5-10DCF 20glycol-PEVs and 10DCF 
10Trc-PEVs, were soft-solid like indica-
ting a change on packing assembly and/
or vesicle interactions. A similar physical 
state was not observed in formulations 
previously prepared using not-hydroge-
nated phosphatidylcholine, Transcutol or 
propylene glycol and diclofenac sodium 
salt, these vesicles appeared viscous in-
stead (Manconi et al. 2009, 2012; Manconi, 
Caddeo, et al. 2011).
Cryo-TEM microscopy was used to ob-
serve structure and morphology of lipo-
somes and PEVs. It is a valid imaging te-
chnique able to ensure a truthful sample 
observation because the sample remains 
as native as possible, without the aid of 
staining and drying process. Empty and 
Figure 1. Cryo-TEM micrographs of 
5DCF control liposomes (A), 5DCF 
5PG-PEVs (B), 10DCF 10PG-PEVs (C), 
and 10DCF 20Trc-PEVs (D).
A
C
B
D
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DCFNa loaded liposomes were mostly 
unilamellar with a spherical shape (Figure 
1A). PEVs exhibited a peculiar behavior 
by forming mainly unilamellar vesicles 
that were closely packed (Figure 1B and 
C), especially 20glycol-PEVs, where bi-
layers forming bridges between the ve-
sicles were visualized (Figure 1D). Empty 
liposomes had a mean diameter around 
160 nm, whereas the addition of DCFNa 
(5 or 10 mg/ml) allowed a reduction of ve-
sicle size to ∼95 nm (p < 0.01) (Table 2). 
Vesicle size reduction is commonly obser-
ved after incorporation of DCFNa, possi-
bly because its amphiphilic properties is 
able to self-associate and to fit within the 
bilayer causing (at high concentration) 
disruption and solubilization similar to 
that induced by detergents (Lopes et al. 
2004; Schreier et al. 2000; Schütze and 
Müller-Goymann 1998). Zeta potential of 
empty liposomes was slightly negative 
(−6 mV) because at pH 7.0, phosphate 
groups of phosphatidylcholine were char-
ged and oriented on liposome external 
surface (Abramović et al. 2008). Zeta po-
tential of DCFNa containing liposomes 
was more negative (−29 mV) suggesting 
the adsorption of the negative charged 
molecules of drug on the bilayer surfa-
ce. 5-10DCF 5-10glycol-PEVs showed a 
mean diameter ranging from 80 to 124 
nm, smaller (p < 0.05) than that of empty 
liposomes, except for 10DCF 10Trc-PEVs. 
DCFNa loaded 20glycol-PEVs were the 
largest vesicles (p < 0.05) and it was no-
ted that mean diameter increased as the 
concentration of glycols increased, with 
the exception of 5DCF 5PG-PEVs and 
5DCF 10PG-PEVs that showed almost 
the same diameter (p > 0.05). The simul-
taneous presence of drug and glycols in 
PEVs led to a lower negative zeta poten-
tial than that of DCFNa loaded liposomes 
(∼−28 mV) as the glycol concentrations 
increased.
The smallest vesicles of tested samples 
were 10DCF 5PG-PEVs (80 nm) pro-
bably because this concentration of drug 
and PG allowed the best phospholipid 
packing. These vesicles exhibited as well 
an adequate negative zeta potential (−17 
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Table 2. Mean diameter, polydisper-
sity index (PI), zeta potential (ZP), 
encapsulation efficiency (EE%), and 
aggregation efficiency (AE%) of P90H 
liposomes and PEVs. Mean values ± 
standard deviation are reported (n = 6).
 Sample
 Empty liposomes
5DCF liposomes
5DCF 5Trc-PEVs
5DCF 10Trc-PEVs
5DCF 20Trc-PEVs
5DCF 5PG-PEVs
5DCF 10PG-PEVs
5DCF 20PG-PEVs
DCFNa
(mg/ml)
0
5
5
5
5
5
5
5
10
10
10
10
10
10
Size
(nm)
160±8
97±7
105±4
119±9
178±6
111±8
100±4
159±6
124±5
157±8
208±9
80±13
109±13
193±16
PI
0.31±0.04
0.31±0.01
0.28±0.09
0.31±0.02
0.32±0.01
0.31±0.04
0.24±0.06
0.26±0.04
0.24±0.06
0.32±0.03
0.33±0.02
0.26±0.06
0.25±0.02
0.30±0.07
ZP
(mV)
-6±2
-29±4
-8±2
-1±3
-1±2
-6±4
-3±2
-2±3
-16±4
-5±3
-3±4
-17±5
-13±4
-2±2
EE
(%)
58±3
61±6
60±2
57±4
61±1
54±3
58±3
50±6
46±2
51±4
47±5
45±4
50±4
AE
(%)
98
95
96
99
86
98
99
91
99
96
92
92
95
89
10DCF 5Trc-PEVs
10DCF 10Trc-PEVs
10DCF 20Trc-PEVs
10DCF 5PG-PEVs
10DCF 10PG-PEVs
10DCF 20PG-PEVs
10DCF liposomes 10 94±4 0.32±0.02 -28±5 53±5 99
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mV) able to assure a good stability. The 
smallest size among Trc-PEVs was obtai-
ned whit 5DCF 5Trc-PEVs (105 nm) whi-
ch however showed a slightly negative 
zeta potential insufficient to ensure a 
good stability of the dispersions. Then, 
Trc-PEVs reached the best packing and 
consequently smaller vesicle size with 5 
mg/ml of DCFNa while PG-PEVs allowed 
the smallest vesicle size with 10 mg/ml 
of DCFNa showing a superior ability of 
phospholipid/PG mixture to provide a su-
itable carrier able to entrap the highest 
amount of drug in the smallest vesicles.
Encapsulation efficiency was quite the 
same for all the tested formulations and 
was slightly higher for 5DCF PEVs than 
that of corresponding 10DCF PEVs pro-
bably because in the latter case the drug 
amount used was 2-fold higher, thus rea-
ching vesicle saturation. Actually, 10DCF 
PEVs encapsulated an higher drug 
amount (∼4.8 mg/ml) than 5DCF vesicles 
(∼3 mg/ml). Whereas, the glycol structure 
and concentration, did not affect the en-
capsulation efficiency.
Aggregation efficiency, expressed as the 
percentage of phosphatidylcholine after 
dialysis with respect to the initial amount, 
seems to be affected by glycol concen-
tration but not by drug concentration. 
Aggregation efficiency was statistically 
similar for all 5-10DCF 5-10glycol-PEVs 
(91–99%) and slightly decreased only for 
5-10DCF 20glycol-PEVs; probably this 
amount of glycol, which is able to decre-
ase the dielectric constant of the medium 
with respect of water, partially solubilized 
a small fraction of phospholipids that re-
main in the free form within the disper-
sion.
4.3.2. Stability during storage of lipos-
omes and PEVs
Physico-chemical features (average size, 
zeta potential, and drug leakage) of the 
tested formulations were checked du-
ring 90 days to evaluate the system sta-
bility. Mean diameter of 20Trc-PEVs and 
20PG-PEVs (Figure 2A and C) at 60 or 90 
days strongly increased, especially 5DCF 
20PG-PEVs that exceed 1 μm after 60 
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days whereas 5-10DCF 20Trc-PEVs and 
10DCF 20PG-PEVs reached a maximum 
diameter of 800 nm. 5-10glycol-PEVs 
were almost stable and their size did not 
exceed 300 nm.
During the storage all the tested samples 
released increasing amounts of drug (Fig. 
2B and D). The lose of drug was more 
evident in 20glycol-PEVs that were in soft 
solid-like tate; this sample also showed a 
strong increase in size due to vesicle ag-
gregation and fusion. Aggregation phe-
nomena of vesicle dispersions is control-
led by a balance of attraction forces and 
electrostatic repulsion forces. In this case, 
the low surface charge of 20glycol-PEVs 
(±5 mV) was unable to ensure an electro-
static repulsion enough to prevent vesicle 
aggregation and fusion, thus promoting 
drug release during storage.
 
4.3.3. DSC studies
DSC is a sensitive thermodynamic tech-
nique which has been extensively used 
to evaluate thermotropic phase of pho-
spholipid vesicles and their transition 
from gel to liquid-crystalline state (Thom-
as and Finnin 2004). Table 3 reported the 
transition temperatures obtained for each 
formulation. Empty liposomes were cha-
racterized by a single endothermic peak 
at 54 ± 0.5 ˚C, characteristic of a coope-
rative gel to liquid-crystalline main phase 
transition. Pretransition peak was aboli-
shed by the addition of cholesterol and 
by the presence of free fatty acids and tri-
glycerides in the soy lipid mixture called 
P90H (MANCONI et al. n.d.). The addi-
tion of DCFNa clearly reduced the tran-
sition temperature of all tested formula-
tions from ∼54 ˚C to ∼50 ˚C, probably due 
to an increase of vesicle curvature (cor-
responding to a vesicle size reduction) 
caused by the drug intercalation on bi-
layer structure, thus modifying its packing 
(Feitosa, Barreleiro, and Olofsson 2000). 
5DCF and 10DCF liposomes showed the 
same transition temperature at 50 ± 0.4 
˚C demonstrating that the drug is able to 
perturb the bilayer structure regardless of 
its concentration in the range studied. In 
PEV formulations the reduction of tem-
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Figure 2. Mean diameter and DCFNa 
entrapment efficiency during 90 days 
of storage. Mean diameter (A) and 
encapsulation efficiency (B) of 5 mg/
ml DCFNa loaded vesicles. Mean 
diameter (C) and encapsulation 
efficiency (D) of 10 mg/ml DCFNa 
loaded liposomes and different PEVs. 
Mean values ± standard deviation are 
reported (n = 6).
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Table 3. Main transition temperature 
(Tt) of P90H liposomes and glycol-PE-
Vs obtained by DSC investigation. 
Unilamellar (ULV) or oligolamellar 
(OLV) vesicles, lamellar spacing (d), 
bilayer thickness (dB), distance of hea-
dgroup from the center of the bilayer 
or lipid half extent (ZH), polar head 
amplitude (σh) and WAXS distance 
calculated from scattering curve of 
empty and DCFNa-loaded liposomes 
and glycol-PEVs. Each single value 
represents the average ± standard de-
viation of three determinations.
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 Sample
 Empty liposomes
5DCF liposomes
5DCF 5Trc-PEVs
5DCF 10Trc-PEVs
5DCF 20Trc-PEVs
5DCF 5PG-PEVs
5DCF 10PG-PEVs
5DCF 20PG-PEVs
10DCF liposomes
Dwaxs
(Å)
4.2Pβ’
4.2Pβ’
4.2Pβ’
4.2Pβ’
-
4.2Pβ’
4.2Pβ’
4.2Pβ’
4.2Pβ’
4.2Pβ’
4.2Pβ’
-
4.2Pβ’
4.2Pβ’
4.2Pβ’
Tt
(°C)
54±0.5
50±0.4
50±0.4
50±0.4
51±0.3
51±0.4
49±0.5
51±0.3
50±0.4
49±0.5
49±0.3
50±0.3
50±0.4
49±0.4
50±0.5
structure
ULV
ULV
ULV
ULV
-
ULV
ULV
ULV
ULV
ULV
OLV
-
ULV
ULV
OLV
d
(Å)
nd
nd
nd
nd
-
nd
nd
nd
nd
nd
60±2
-
nd
nd
50±0.4
Zh
(Å)
20.6±0.5
17.3±0.3
16.5±0.5
15.8±0.6
-
16.4±0.3
16.4±0.5
16.5±0.4
15.8±0.3
15.6±0.4
15.5±0.4
-
15.2±0.3
15.9±0.5
15.8±0.3
σh
(Å)
2.8±0.3
2.2±0.2
1.9±0.3
1.4±0.4
-
1.9±0.5
1.2±0.4
2.1±0.3
1.4±0.3
1.4±0.2
1.1±0.3
-
1.7±0.2
1.4±0.3
1.3±0.2
db
(Å)
58.8±3
53.0±3
41.0±1
37.0±2
-
40.8±2
37.6±1
41.8±2
37.8±2
37.0±1
36.0±1
-
38.6±2
37.8±2
36.8±1
10DCF 5Trc-PEVs
10DCF 10Trc-PEVs
10DCF 20Trc-PEVs
10DCF 5PG-PEVs
10DCF 10PG-PEVs
10DCF 20PG-PEVs
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perature transition was slightly depen-
dent on the drug concentration. A low 
reduction (∼1 ˚C) has been observed as 
the drug concentration increased: 10DCF 
PEVs showed lower transition temperatu-
re than that of the corresponding 5DCF 
PEVs, probably because the simultane-
ous drug and glycol intercalation, within 
the bilayer surface, allowed the formation 
of an interdigitated bilayer. Glycols slight-
ly altered the transition temperature and 
the resulting effects depended on their 
structure and concentration. This phe-
nomenon probably can be due to their 
presence in the inter-vesicle spaces whe-
re led a reduction of the dielectric con-
stant of the medium, thus reducing the 
charged groups on the interfacial bilayer 
region and inducing a series of intra- and 
inter-vesicle transformations (Rosser et al. 
1999; Vierl et al. 1994)(Manconi et al. 2012).
4.3.4. Small- and wide-angle X-ray scat-
tering analysis
The molecular rearrangements that take 
place in vesicles were confirmed by SWA-
XS, a useful tool to investigate microsco-
pic change inside phospholipid bilayer 
that provides detailed information at the 
molecular level about the influence of 
external compounds on the lamellar or-
ganization of vesicles. WAXS diffraction 
peak of empty liposomes was asymme-
tric, diffuse and centered at ∼1.52 Å−1 
confirming the bilayer state in Lβ′ phase 
in which the hydrocarbon chains were ful-
ly extended and tilted with respect to the 
bilayer surface. The presence of DCFNa 
and glycols on phospholipid vesicles led 
to a more resolved and sharp peak shi-
fted at ≈1.51 Å−1 evidencing the bilayer 
transition to Pβ′ phase in which the lipid 
chains were differently organized (Figure 
3A).
The incorporation of DCFNa into liposo-
mes led to a marked alteration of lipid 
layer arrangement and chain packing 
(Figure 3B and Table 3). SAXS profiles of 
empty liposomes showed a pure diffuse 
scattering curve indicating the presence 
of unilamellar vesicles; the SAXS curves 
became broadened and low-intense 
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Figure 3. WAXS intensity profile 
versus the scattering vector modulus 
(q) reordered from empty liposo-
mes, 5-10DCF liposomes and 5DCF 
20PG-PEVs (A); SAXS curves as a 
function of the scattering vector mo-
dulus (q) of empty, 5DCF and 10DCF 
liposomes, (B); 10DCF liposomes 
and 10DCF PG-PEVs (C); 10DCF 
20Trc-PEVs (D). For the sake of clarity 
only the more representative curves 
were reported.
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when DCFNa was incorporated, as a re-
sult of the strong interaction of the drug 
with the lipid bilayer. The related bilayer 
thickness (dB) estimated from Bragg’s 
law decreased from 56.8 ± 0.6 to 53.0 
± 0.6, to 37.8 ± 0.6 Å for empty, 5DCF 
and 10DCF liposomes respectively, with 
a simultaneous reduction of polar head 
amplitude (σh) and lipid half extent (ZH). 
According to DSC results the drug in-
tercalation between the polar heads of 
phospholipids allowed the formation of 
free spaces in the hydrophobic region 
between achyl chains that moved toward 
the opposite surface reducing the bilayer 
thickness (dB 38 Å). The membrane un-
derwent a transformation to interdigita-
ted structure (Pβ′) confirmed by lower dB 
value and sharp WAXS peak.
Also, the association of glycols and DCF-
Na, promoted a series of structural chan-
ges which led to the bilayer transition to 
the Pβ′ interdigitated phase. These arran-
gements depending on glycol chemical 
structure and concentration were evalua-
ted according to modifications on SAXS 
profile and correlated parameters (Figu-
re 3C and Table 3). Liposomes, 5DCF 
PEVs (except 5DCF 20Trc-PEVs), 10DCF 
5Trc-PEVs and 10DCF 5-10PG-PEVs were 
always unilamellar presenting a first order 
diffraction peak centered at ~0.11 Å−1 
for 5DCF vesicles and shifted at ~0.14 
Å−1 for 10DCF vesicles. The first order 
peak of 10DCF 10Trc-PEVs and 10DCF 
20PG-PEVs appeared at ~0.12 Å−1 and 
presented a shoulder at ~0.18 Å−1 due 
to the presence of a different population 
of multilamellar vesicles. All PEVs were 
in the interdigitated phase as confirmed 
by the low bilayer thickness (dB ~ 38 
Å) and a WAXS sharp peak. The bilayer 
thickness reduction was associated to a 
simultaneous decrease of polar head am-
plitude (σh) and lipid half width (ZH). As 
reported previously, Transcutol and DCF-
Na interacted together with the polar bi-
layer surface, producing empty spaces at 
bilayer midplane, forming an acyl-chain 
interdigitation and a consequent com-
pression of bilayer thickness and packing 
rearrangements on vesicle structure and 
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morphology (Manconi et al. 2012).
Important structural changes were obser-
ved in SAXS patterns of 20glycol-PEVs, 
especially 5-10DCF 20Trc-PEVs, as a re-
sult of a combined effect of both DCFNa 
and glycols. Indeed, DCFNa promoted 
bilayer interdigitation, while glycols at 
high concentration, probably underwent 
a change of phospholipid partition betwe-
en vesicle bilayers and water medium. In 
fact, they decrease the solvent dielectric 
constant and as a result the number of 
ionized groups on the interfacial bilayer 
region (confirmed by lower negative zeta 
potential). As a final consequence, a par-
tial solubilization of lipid chains of pho-
spholipid on glycol/water medium can 
be observed, with the formation of inter-
connected, closely packed or multiwal-
led vesicles. The SAXS pattern reported 
in Figure 3D shows the effect of DCFNa 
and Trc (20%) on 5-10DCF 20Trc-PEVs. 
Several quasi-Bragg peaks indicating a 
multilamellar system can be observed in 
coexistence with other signals. On these 
basis, according to the cryo-TEM images 
(Figure 1D), a coexistence of unclosed 
bilayers and unilamellar vesicles can be 
supposed.
4.3.5. Rheological studies
To better understand the structural mo-
difications that underwent on vesicle di-
spersions and to explain the physical state 
changes from liquid to high viscous liquid 
or soft-solid like, rheological studies were 
carried out as well. Frequency sweep and 
viscometry tests were performed: the sto-
rage modulus (G′ at 1 Hz) and viscosity 
values (at shear rate 1 s−1) were used to 
compare the viscoelastic properties of 
the different dispersions. Storage modu-
lus of each formulation was affected by 
the concentration and in a less extent 
by the structure of glycols while it was 
not significantly influenced by the pre-
sence of the drug: 5-10DCF liposomes 
showed a comparable storage modulus 
value (~1 × 10−2) confirming that these 
systems were low viscous and unstructu-
red fluids (Figure 4A and B). The storage 
modulus of PEVs increased as Transcutol 
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Figure 4. Storage modulus (G′) values 
collected at 1 Hz of 5DCF liposomes 
and 5DCF glycol-PEVs (A and C) and 
viscosity data collected at 
1 Pa s−1 of 10DCF liposomes and 
10DCF glycol-PEVs (B and D).
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or propylene glycol concentration incre-
ased reaching values about 3–5 orders 
of magnitude higher than that of lipo-
somes especially for 5-10DCF 20Trc-PE-
Vs (~4 × 103) and 5-10DCF 20PG-PEVs 
(~6 × 103) that generated a solid like 
system probably due to the formation of 
closely packed and interconnected vesi-
cles. 10glycol-PEVs showed storage mo-
dulus values between that of liposomes 
and that of 5-10DCF 20glycol-PEVs and 
their macroscopic behavior, as reported 
in Table 1, was typical of highly viscous 
liquids or soft-solid (10DCF 10Trc-PEVs). 
Viscometry experiments (Figure 4C and 
D) confirmed the above reported ob-
servations. As the glycol concentration 
increased, the viscosity of the system in-
creased correspondingly, 5-10DCF lipo-
somes showed a shear viscosity of about 
2 × 10−3 Pa s−1; the presence of glycols 
at low concentration (5glycol-PEVs) led to 
a slight increase of system viscosity (~1 
× 10−1/−2 Pa s−1) whereas the effect 
was much more evident in 10-20Trc-PEVs 
and 10-20PG-PEVs (viscosity ~3 × 105 Pa 
s−1).
Thermotropic and mechanical properties 
of vesicle dispersion confirmed that the 
drug alone was able to modify the inter-
nal bilayer packing forming an interdigi-
tated structure but it did not change in-
tervesicle architecture whereas Transcutol 
and propylene glycol showed a concen-
tration-dependent ability to modify the 
vesicle assembly as well as the inter-ve-
sicle structure. Glycol presence on water 
phase led to a reduction of dielectric con-
stant (compared to that of water) and a 
consequent increase of phospholipid acyl 
chain solubility in the external medium of 
vesicles. In this environment phospholi-
pids changed their orientation turning 
their hydrophobic tails to the glycol/PBS 
mixture and interacting with other tails 
of close vesicles to form a tridimensional 
network of close packed and intercon-
nected vesicles as confirmed by the high 
values of storage modulus and viscosity. 
The formation of vesicle interconnections 
associated to bilayer rearrangements that 
led to an increase of vesicle size (>155 
81
nm) and lamellarity and to a reduction 
of free inter-vesicle solvent resulted in 
macroscopical change of vesicle physical 
state from liquid to solid for 20glycol-PE-
Vs and 10DCF 10Trc-PEVs.
4.4. Conclusion
This work underlines the significant ef-
fects of water miscible cosolvents on 
phospholipid vesicle assembly structu-
re. Using hydrosoluble glycols such as 
Trc or PG to prepare hydrogenated soy 
phosphatidylcholine vesicles entrapping 
DCFNa, highly viscous liquid or soft-solid 
system can be obtained thanks to the for-
mation of new interaction forces between 
drug, glycols and phospholipids. Col-
lected results evidenced the existence of 
a complex architecture in which vesicles 
were closely packed and interconnected 
forming a tridimensional network that is 
responsible for the high viscous/soft solid 
like behavior of the system. The highly vi-
scous or solid like systems might facilitate 
the skin application of drug and increase 
its residence time at the application site.
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5. fabbrIcatIon of quercetIn and curcumIn 
bIonanovesIcles for the preventIon and rapId regeneratIon of full-thIckness skIn defects on mIce
5.1. Introduction
Polyphenols are widely distributed in 
plants and plant-derived foods, including 
vegetables, fruits, tea, spices, wine, be-
verages, and nutritional supplement pro-
ducts. In previous studies they have been 
proposed as therapeutic agents against 
several acute and chronic diseases, such 
as Alzheimer and Parkinson, multiplescle-
rosis, cardiovascular diseases, allergies, 
and certain types of cancer (Prasain and 
Barnes 2007). These advantages are at-
tributed to their useful antioxidant and 
anti-inflammatory properties that regula-
te cell proliferation and function by pre-
venting the onset and progression of the 
aforementioned diseases (Lee et al. 1998) 
(Appleton 2003; Nichols and Katiyar 2010; 
Panchatcharam et al. 2006; Phan et al. 
2001). Although phase I clinical trials have 
shown polyphenols as safe drugs even at 
high doses, poor bioavailability, poor ab-
sorption, rapid metabolism, and systemic 
clearance hamper their use in pre-clinical 
and clinical models. Indeed, polyphe-
nols like curcumin, resveratrol, querce-
tin, and others, are poorly absorbed in 
the gastrointestinal tract and undergo 
fast metabolism by the liver (Prasain and 
Barnes 2007; Yallapu, Jaggi, and Chauhan 
2012). Moreover, clinical trials exploring 
different schedules of administration of 
polyphenols, especially quercetin (QUE) 
and curcumin (CUR), have been hampe-
red by their extreme water insolubility 
(Figure 1). To overcome such limitations, 
various natural polyphenols have been 
formulated in innovative nanovesicles 
to be administered by the dermal route 
(Caddeo, Manconi, et al. 2013; Pando et 
al. 2013). The topical application of com-
pounds with free-radical scavenging and 
anti-inflammatory properties in patien-
ts has shown a significant improvement 
in wound healing and protection from 
oxidative damage. In particular, querce-
tin and curcumin may be promising for 
wound healing, thanks to their ability to 
inhibit reactive oxygen species and tissue 
inflammation (Gomathi et al. 2003; Gopi-
nath et al. 2004; Mohanty, Das, and Sahoo 
2012; Phan et al. 2001; Süntar et al. 2010). 
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Topical chronic non-healing wound is a 
complex multifactorial process involving 
the interplay of several cellular and bio-
chemical mechanisms that compromise 
the viability of superficial tissues (epider-
mis and dermis). Inflammation, which con-
stitutes a part of the acute response, re-
sults in a coordinated influx of neutrophils 
at the wound site, that produces and re-
leases inflammatory mediators, such as 
tumor necrosis factor alpha (TNF-α) and 
interleukin-1 (IL-1). Neutrophils contain 
high levels of destructive proteases and 
oxygen free radicals that are released into 
the local wound area when cells die.
This can cause extensive tissue damage 
and prolong the inflammatory phase. 
Non-phagocytic cells also generate free 
radicals, leading to an accumulation of 
oxygen and nitrogen reactive species at 
the wound site. These radicals will result 
in oxidative stress causing lipid peroxida-
tion, DNA breakage, and enzyme inacti-
vation, including free radical scavenging 
enzymes (MARTIN n.d.). One of the major 
causes of delayed healing is the persi-
stence of inflammation or an inadequate 
angiogenic response (Appleton 2003). It 
has been postulated that an anti-inflam-
matory response after cutaneous woun-
ding is a prerequisite for healing. Potent 
antioxidant, anti-inflammatory agents 
such as quercetin, curcumin and resvera-
trol, can play an important role in resto-
ring physiological conditions, allowing 
a significant improvement in wound he-
aling (Gomathi et al. 2003; Gopinath et 
al. 2004; Phan et al. 2001). In the present 
study phorbol ester 12-O-tetradecanoyl-
phorbol-13-acetate, TPA, has been used 
to mimic skin inflammation and ulcera-
tion caused by oxidative stress. TPA, by 
activating protein kinase C, stimulates 
the expression of a wide variety of pro-in-
flammatory cytokines, such as TNF-α, 
and causes rapid influx of neutrophils and 
other innate immune cells into skin. Many 
of the same physiological effects induced 
by TPA occur in chronic wound process. 
Thus, it can be used to mimic chronic skin 
wound (Caddeo, Sales, et al. 2013).
The nanoencapsulation of drugs repre-
OH
HO
OH
OH
O
O
OH
HO OH
OCH3
O O
H3CO
Figure 1. Chemical structure of quer-
cetin (A) and curcumin (B).
A
B
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sents the most convenient way of impro-
ving their skin delivery. Therefore, during 
the past two decades many studies have 
been reported on the use of nanoparti-
cles as carriers for skin delivery. Rationally 
designed nanocarriers may improve the 
therapeutic index of drugs, by modifying 
their pharmacokinetic and biodistribu-
tion. The encapsulation of drugs into 
phospholipid vesicles would significant-
ly alter their in vivo behaviour and many 
studies have revealed that vesicular drugs 
should be regarded as new entities diffe-
rent from free (non-entrapped) drugs.
In the present study, quercetin and cur-
cumin were incorporated in liposomes or 
in innovative Penetration Enhancer con-
taining Vesicles (PEVs) and used as (trans)
dermal drug delivery systems. The drug 
and/or carrier efficacy was evaluated by 
in vitro skin distribution and in vivo abili-
ty to reduce oxidative inflammation and 
neutrophil infiltration induced by TPA in 
mice. The inhibition of these factors is a 
crucial stage to repair chronic wound.
 5.2. Materials and methods
5.2.1 Materials
Lipoid S75 (S75), a mixture of soybean 
phospholipids (70% phosphatidylcholine, 
9% phosphatidylethanolamine and 3% 
lysophosphatidylcholine), triglycerides 
and fatty acids was purchased from AVG 
S.r.l. (Milan, Italy). Octyl-decyl polyglu-
coside (Oramix®CG110, Or) was dona-
ted by Seppic (Milan, Italy). Phosphate 
buffer solution (PBS, pH 7), QUE, CUR, 
polyethylene glycol 400 (PEG400) and 
12-O-Tetradecanoylphorbol 13-acetate 
(TPA) were purchased from Sigma-Aldrich 
(Milan, Italy). 
5.2.2 Sample preparation
Vesicles were prepared using S75, quer-
cetin or curcumin, PBS for liposomes and 
PEG400/PBS or Or/PEG400/PBS for PEVs 
(Table 1). Empty vesicles were used as a 
reference. All components were weighed 
in a glass flask, and left hydrating over-
night in 5 ml of PBS for liposomes, and 
PEG400/PBS or Or/PEG400/PBS for PEVs 
Table 1. Sample composition and 
their acronyms.
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(Chessa et al. 2011; Manconi et al. 2005). 
Then, the suspensions were sonicated (2 
seconds on and 2 seconds off, 50 cycles; 
13 μm of probe amplitude) with a high in-
tensity ultrasonic disintegrator (Soniprep 
150, MSE Crowley, London, United King-
dom). Samples (1 ml) were purified from 
the non-incorporated drug by dialysis 
against PBS or appropriate PEG400/PBS 
or Or/PEG400/PBS mixture (2 L) using 
dialysis tubing (Spectra/Por® membra-
nes: 12–14 kDa MW cut-off, 3 nm pore 
size; Spectrum Laboratories Inc., DG Bre-
da, The Netherlands), during 3 hours at 
25°C, refreshing the medium twice. QUE 
and CUR dispersions in PEG400/PBS mix-
ture were used as controls (Table 1).
5.2.3 Vesicle characterization
Vesicle formation and morphology were 
checked by transmission electron mi-
croscopy (TEM) and cryo-TEM. Liposo-
mes were previously diluted (1:2) with 
PBS and PEVs with PEG400/PBS or Or/
PEG400/PBS. TEM observation was car-
ried out using a JEM-1010 (Jeol Europe, 
Croissy-sur-Seine, France) microscope, 
equipped with a digital camera, at an 
accelerating voltage of 80 kV. A drop of 
diluted vesicular dispersion was applied 
to a carbon film-covered copper grid for 
5 minutes, subsequently dispersion was 
absorbed with filter paper and stained 
with a 1% phosphotungstic acid.
For cryo-TEM analysis, a thin aqueous 
Liposomes
PEG-PEVs
OrPEG-PEVs
10
10
10
240
240
240
-
-
10
-
50
1000
950
950
50 950
Control dispersion - - - 50
 Sample
QUE or CUR
(mg/ml)
S75
(mg/ml)
PEG400
(mg/ml)
Oramix
(mg/ml)
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film was formed by placing a drop of di-
luted sample (1:2) on a glow-discharged 
holey carbon grid and then blotting the 
grid against filter paper. The resulting 
thin films spanning the grid holes were 
vitrified by plunging the grid into ethane, 
which was maintained at its melting point 
with liquid nitrogen, using a Vitrobot (FEI 
Company, Eindhoven, The Netherlands). 
The vitreous films were transferred to a 
Tecnai F20 TEM (FEI Company) using a 
Gatan cryotransfer (Gatan, Pleasanton, 
CA), and the samples were observed in a 
low dose mode. Images were acquired at 
200 kV at a temperature between –170/-
175°C, using a CCD Eagle camera (FEI 
Company, Eindhoven, The Netherlands).
The average diameter and polydisper-
sity index (PI, as a measure of the size 
distribution width), were determined by 
Photon Correlation Spectroscopy (PCS) 
using a Zetasizer nano-ZS (Malvern In-
struments, Worcestershire, United King-
dom). Samples were backscattered by a 
helium-neon laser (633 nm) at an angle of 
173° and a constant temperature of 25°C. 
Just before the analysis, samples were di-
luted 1:1000 using PBS for liposomes and 
PEG400/PBS or Or/PEG400/PBS for PEVs 
to avoid alteration of intervesicle environ-
ment.
Zeta potential was estimated using the 
Zetasizer nano-ZS by means of the M3-
PALS (Mixed Mode Measurement-Phase 
Analysis Light Scattering) technique, whi-
ch measures the particle electrophoretic 
mobility.
Entrapment efficiency (EE%), expres-
sed as the percentage of the amount of 
drug initially used, was determined by 
high performance liquid chromatography 
(HPLC) after disruption of vesicles with 
0.025% non-ionic Triton X-100. QUE and 
CUR content was quantified at 367 and 
424 nm respectively, using a chroma-
tograph Alliance 2690 (Waters, Milano, 
Italy). The column was a SunFire C18 (3.5 
μm, 4.6×150 mm). The mobile phase was 
a mixture of acetonitrile, water and acetic 
acid (94.8:5:0.2, v/v), delivered at a flow 
rate of 1.0 ml/min.
The lipid content of dispersions was 
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determined by the Stewart assay (45). 
Briefly, an aliquot of suspension was ad-
ded to a biphasic mixture of aqueous am-
monium ferrithiocyanate solution (0.1 N) 
and chloroform. The concentration of S75 
was obtained by measuring absorbance 
at 485 nm in the organic solution. The ag-
gregation efficiency (AE%) represented 
the effective amount of aggregated pho-
spholipids expressed as the percentage 
of the amount initially used. 
5.2.4 Small- and Wide-Angle X-ray Sa-
cattering (SWAXS)
SWAXS experiments were carried out 
using a S3-MICRO (Hecus X-ray systems, 
Graz, Austria) coupled to a GENIX-Fox 
3D X-ray source (Xenocs, Grenoble, Fran-
ce) and a 50 focused X-ray beam with 
0.1542 nm at Cu Kα-line. The q range was 
0.003-0.6 Å−1 for SAXS and 1.3-1.9 Å−1 
for WAXS, where q = (4 π sin θ)/λ is the 
modulus of the scattering wave vector, θ 
the scattering angle and λ the wavelen-
gth. The analysis of the dispersions was 
carried out at their native concentration. 
All scattering curves, recorded at 25°C 
were reproduced twice, and a represen-
tative curve was selected, plotting the 
scattering intensity (I) as a function of 
the scattering vector (q). SAXS patterns 
were analyzed in terms of a global model 
using the program GAP (Global Analysis 
Program) developed by Pabst (46) that 
permitted to obtain relevant structural 
parameters on bilayer-based structures, 
i.e. vesicles and lamellar phases. From 
the analysis, the membrane thickness was 
obtained through the definition dB = 2 
(zH + 2 σH). zH and σH derive from SAXS 
curve fitting with GAP.
5.2.5 In vitro skin penetration and per-
meation studies
Experiments were performed on new 
born pig skin using Franz vertical cells with 
an effective diffusion area of 0.785 cm2, 
under non-occlusive conditions. The skin, 
stored at –80°C, was pre-equilibrated in 
saline (0.9% w/v of NaCl) at 25˚C. Skin 
specimens (n = 6 per formulation) were 
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sandwiched between donor and receptor 
compartments. The receptor was filled 
with 5.5 ml of saline, continuously stirred 
and thermostated at 37± 1˚C. Samples 
(20 µl) were applied onto the skin surface 
at 0 and 3 h. At regular intervals, up to 24 
h, the receiving solution was withdrawn, 
replaced with pre-thermostated (37˚C) 
fresh saline and analyzed by HPLC for 
drug content. After 24 h, the skin surface 
was gently washed (3 times) with 1 ml of 
distilled water, then dried with filter pa-
per. The stratum corneum was removed 
by stripping with adhesive tape Tesa® 
AG (Hamburg, Germany). Epidermis was 
separated from dermis with a surgical 
scalpel. Tape strips, epidermis, and der-
mis were cut, placed each in a flask with 
methanol and sonicated for 4 minutes in 
an ice bath to extract the drug. The tapes 
and tissue suspensions were filtered out 
and assayed for drug content by HPLC.
 
5.2.6 In vivo oedema and myeloperox-
idase assays
Female Hsd:ICR(CD-1®) mice (5-6 weeks 
old, 25-35 g) were obtained from Harlan 
Laboratories (Barcelona, Spain) and accli-
matized for 1 week before use. All studies 
were performed in accordance with Euro-
pean Union regulations for the handling 
and use of laboratory animals. The pro-
tocols were approved by the Institutional 
Animal Care and Use Committee of the 
University of Valencia.
The back skin of mice was shaved and 
TPA dissolved in acetone (243 μM; 3 
μg/20 μL) was applied to the shaved dor-
sal area (~ 2 cm2) to induce cutaneous 
inflammation and ulceration (day 1) (fi-
gure 2). Negative control mice received 
acetone only (20 μL). All test compounds 
(20 μL), were topically smeared over the 
same dorsal site 3 and 6 h after TPA ap-
plication. The procedure was repeated (at 
24-h intervals) on day 2 and 3. On day 
4, mice were sacrificed by cervical dislo-
cation. Each group comprised four mice 
(figure 3). The inhibitory effect of test 
compounds on inflammation and ulcera-
tion was determined by two biomarkers: 
oedema formation and myeloperoxidase 
Figure 2: In vivo inflammatory studies 
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Figure 3: Schematic representation of 
the study
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(MPO) activity. The dorsal treated skin 
area of sacrificed mice was excised, wei-
ghed to assess any increase indicative of 
oedema formation. MPO assay was per-
formed following the previously reported 
method (Caddeo, Sales, et al. 2013; Sato 
et al. 1996). Briefly, skin biopsies were ho-
mogenized and centrifuged, the superna-
tant was incubated with hydrogen peroxi-
de and tetramethylbenzidine and then 
assayed for MPO activity spectrophoto-
metrycally at 620 nm. The MPO activity 
was calculated from the linear portion of 
a standard curve.
5.2.7 Histological examination
Skin biopsies (~ 2 cm2) were excised from 
mice treated region, after 72 hours of 
treatment (on day 4), and maintained in 
formaldehyde (10% v/v). Tissue samples 
were processed routinely and embedded 
in paraffin wax. Longitudinal sections (5 
μm) were stained with haematoxylin and 
eosin. Microscopic assessment by light 
microscope was performed blind on co-
ded slices.
 
5.2.8 Statistical analysis of data
Results are expressed as the mean±s-
tandard deviation. Analysis of variance 
(ANOVA) and Bartlet’s test for homoge-
neity of variance were performed using 
IBM SPSS statistics for Windows. Post hoc 
testing (P <0.05) of the multiple compa-
risons was performed by the Scheffe or 
Dunnet tests.
5.3. Results
The chemical structure of polyphenolic 
QUE and CUR is reported in Figure 1. 
QUE is a yellow-green, polyphenolic fla-
vonol containing the 3-hydroxyflavone 
backbone with 5 oxydrilic groups in posi-
tion 3’-4’ and 3-5-7 (Figure 1A). CUR is a 
yellow-orange polyphenol formed by two 
aromatic o-methoxy phenolic groups, 
linked by a seven-carbon chain with a 
β-diketone (Figure 1B). Under physiologi-
cal conditions, CUR can exist in both an 
enol and a bis-keto form, which coexist in 
equilibrium. These phytochemicals were 
entrapped in phospholipid vesicles and 
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Figure 3. Representative SAXS dif-
fraction profiles of empty liposomes 
and PEVs. Empty liposomes
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Table 3. Selected fitting parameters 
and derived parameters for SAXS 
curves (n=3) of empty and QUE or 
CUR loaded vesicles. Vesicles were 
oligolamellar (OLV) or multilamellar 
(MLV). All distances are given in Å: re-
petition distance or lamellar thickness 
(d); polar head amplitude (σh); polar 
head distance to the centre of bilayer 
corresponding to lipid half extent 
(Zh); bilayer thickness (dB), water layer 
thickness (dW).
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the results of their nanoformulation and 
application on the skin are presented. All 
the vesicles were prepared using S75, 
a mixture of soybean lipids containing 
mainly phosphatidylcholine, and in minor 
amounts phosphatidylethanolamine, ly-
sophosphatidylcholine, triglycerides and 
fatty acids (Table 1). S75 was used at a 
high concentration (240 mg/ml) to effi-
ciently entrap 10 mg/ml of phytodrugs. 
To prepare PEVs, one (PEG400) or two 
(PEG400 and Oramix) hydrophilic sur-
factants were added to the water phase. 
Table 2 summarizes the physicochemical 
features of the prepared liposomes and 
PEVs.
Empty liposomes’ size was 121±8 nm, and 
the addition of the surfactants resulted in 
an increase in size (p<0.05) that was more 
evident when surfactants were simulta-
neously used in OrPEG-PEVs (p<0.01). 
The presence of quercetin did not affect 
vesicle size (p>0.05), while curcumin cau-
sed an enlargement of vesicles. Particle 
Empty PEG-PEVs
Empty OrPEG-PEVs
QUE liposome
QUE PEG-PEVs
QUE OrPEG-PEVs
MLV
MLV
OLV
MLV
17±03
16±03
 17±0.5
16±0.4
4±0.4
6±0.3
3±0.3
6±0.3
61±0.1
60±0.1
60±0.2
60±0.3
52±2
46±2
55±2
53±2
54±2
8±1
5±1
7±1
6±1
CUR liposomes
CUR PEG-PEVs
CUR OrPEG-PEVs
MLV
OLV
MLV
MLV
16±0.6
17±0.7
16±0.3
16±0.4
5±0.5
4±0.4
6±0.2
6±0.6
74±0.5
72±0.3
60±0.2
59±0.3
47±3
49±2
55±3
54±3
27±2
23±2
5±1
5±1
 Empty liposomes OLV 17±05 3±0.4 78±0.4 32±1
 Sample
structure Zh σh d dB dW
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Figure 2. Cryo-TEM micrographs of 
QUE-loaded liposomes (A), CUR-lo-
aded liposomes (B), QUE-loaded 
PEG-PEVs (C) and CUR-loaded 
PEG-PEVs (D). Negative stain TEM mi-
crographs of QUE-loaded OrPEG-PE-
Vs (E) and CUR-loaded OrPEG-PEVs 
(F). Bars represent 100 nm.
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size distribution was broad (PI<0.37) but 
always repeatable and was smaller for 
quercetin-loaded vesicles (PI<0.26). Zeta 
potential value was slightly negative (~ 
-10 mV) for all the samples, independent-
ly of their composition. Incorporation effi-
ciency was ~ 64% for both drugs, without 
statistical differences (p>0.05) among 
liposomes and PEVs. Aggregated pho-
spholipids were around 70% in liposomes 
and around 63% in PEVs, probably due 
to their partial solubilisation by PEG400.
Vesicle formation and morphology were 
confirmed by TEM and cryo-TEM inve-
stigation (Figure 2). Vesicles appeared 
always spherical and lamellar, but the 
number of lamellae increased in the pre-
sence of PEG400 (PEVs). 
Complementary information on vesicle 
structure can be obtained from SWAXS 
studies that permit to explore the mo-
lecular packing of phospholipids in both 
head group and acyl chain regions. The 
WAXS patterns of all tested vesicles were 
characterized by a very diffuse scattering, 
without evident signal, confirming the 
vesicle state in liquid-crystalline form in 
which the lipid acyl chains of bilayer are 
disordered (data not shown). Represen-
tative SAXS diffractograms and deduced 
parameters are reported in Figure 3 and 
Table 3. 
Analyzing the curves of empty and loa-
ded liposomes, only a first order sharp 
diffraction peak is observed at 0.08 Å-1 
with a shoulder at 0.09 Å-1, which indica-
tes the presence of a small population of 
oligolamellar vesicles (2-5 bilayers). The 
presence of PEG400 and Oramix in PEVs 
altered the patterns: a sharp reflection is 
observed at 0.10 Å-1 with a symmetric 
profile, and a second order peak at 0.21 
Å-1, confirming the change to multila-
mellar structures (Figure 3). The patterns 
of QUE and CUR liposomes and PEVs 
were similar to that of empty vesicles. 
In comparison with empty liposomes, 
PEVs showed a higher polar head ampli-
tude (σH, from 3 to 6 Å) and bilayer thi-
ckness (dB, from 46 to 55 Å), while their 
polar head distance to the centre of the 
bilayer, corresponding to lipid half extent 
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(zH, from 17 to 16 Å), and the repetition 
distance or lamellar thickness (d, from 78 
to 60 Å) were lower. The most significant 
modification of SAXS parameters was ob-
served in the reduction of water layer thi-
ckness (dw) that in liposomes was ~ 27 Å 
and in PEVs decreased to ~6 Å, showing 
a significant contraction of interlamellar 
spaces in the presence of hydrophilic sur-
factants. The trend was the same for QUE 
and CUR liposomes and PEVs. Concer-
ning the interaction of phytodrugs with 
liposomal bilayer, QUE led only to a slight 
reduction of lamellar thickness (d, from 78 
to 74 Å), whereas CUR increased both the 
polar head amplitude (σH, from 3 to 4 Å) 
and the bilayer thickness (dB, from 46 to 
49 Å) and reduced the lamellar thickness 
(d, from 78 to 72 Å).
Skin delivery capability of QUE- and 
CUR-loaded liposomes and PEVs was 
evaluated in vitro under non-occlusive 
conditions using Franz diffusion cells (Fi-
gure 4). Quercetin and curcumin depo-
sition and permeation were similar: the 
highest accumulation was reached in the 
stratum corneum, with a minimum value 
(15%) for drug dispersions and a maxi-
mum value (~28%) for liposomes and 
PEVs (p>0.05). Drug deposition in epi-
dermis was lower for all the formulations 
and control dispersions, and ranged from 
1.5% for drug dispersions and curcu-
min-loaded OrPEG-PEVs to 3.1% for the 
other ones. The accumulation in dermis 
and receptor fluid was even lower (≤1%) 
and without statistical differences among 
the different formulations (p>0.05).
As previously reported, TPA daily applied 
on dorsal mouse skin during 3 days in-
duced skin ulceration (~2 cm2), loss of 
epidermis integrity, crust formation and 
biological alterations on dermis and 
subcutaneous tissue (Caddeo, Sales, et 
al. 2013). Histopathological analysis of 
hematoxylin and eosin stained TPA-trea-
ted skin revealed the complete absence 
of epidermis in the central area of injury 
and a marked infiltration of leukocytes 
(neutrophils and eosinophils) in dermis, 
subcutaneous and muscle tissue, and a 
severe vascular congestion (Figures 5C 
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and D). Skin treated with TPA and sub-
sequent quercetin or curcumin disper-
sions, showed an extensive damage of 
epithelium with localized keratinization 
in several sites, an evident infiltration of 
leukocytes in dermis and in subcutaneous 
tissue and vascular congestion (Figure 
5E). 
In TPA-inflamed skin subsequently trea-
ted with QUE and CUR bionanovesicles, 
there were areas extensively keratinized 
with thick crusts and others with a thin 
layer of migrating epithelium over the 
dermis, indicating the epidermis reforma-
tion. Leukocyte infiltration was less seve-
re, especially in dermis, and congestion 
of blood vessels was less evident (Figures 
5F and G). In CUR PEG-PEVs an extensive 
reepithelization of the skin with multiple 
layers of thick epidermis was observed. 
Connective tissue, and collagen fibres 
were arranged, leukocyte infiltration was 
moderate and limited to ipodermis and 
no vessel congestion was observed (Fi-
gure 5H). 
When TPA treatment was associated (after 
3 and 6 h) to quercetin or curcumin local 
applications, the skin lesion and inflam-
mation were inhibited, depending on the 
polyphenol and the carrier used. All the 
tested samples, even empty vesicles and 
quercetin and curcumin dispersions sup-
pressed TPA-induced oedema (p<0.05) 
and showed an oedema inhibition ran-
ging from 50 to 91%. Curcumin-loaded 
PEG-PEVs provided the highest oedema 
inhibition (91%): this value was statisti-
cally different from the other curcumin 
formulations (Table 4). The level of MPO 
activity is directly proportional to the 
neutrophil concentration in the inflamed 
tissue. In this work, we used MPO activi-
ty as a quantitative assay to evaluate the 
polyphenol anti-inflammatory efficiency 
in wound tissue (Table 4). Quercetin- and 
curcumin-loaded liposomes and PEVs 
showed a superior ability, over phyto-
drug dispersions, to reduce MPO activi-
ty in damaged tissue and the inhibition 
value was higher, especially for quercetin 
liposomes (59%) and curcumin liposomes 
and PEG-PEVs (~68%). Quercetin PEVs 
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Table 2. Mean diameter (MD), polydi-
spersity index (PI), zeta potential (ZP), 
entrapment efficiency (EE) and aggre-
gation efficiency (AE) of empty and 
quercetin (QUE) or curcumin (CUR) 
loaded vesicles. Mean values±stand-
ard deviation (SD) were obtained from 
at least 6 samples. 
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achieved only 40% of MPO inhibition and 
the other samples did not have statistical 
significance, as compared to the TPA-tre-
ated skin. 
5.4. Discussion
In the present investigation effective pho-
spholipid bionanovesicular formulations 
were developed to achieve maximum 
loading capacity and optimal skin deli-
very of two natural phytodrugs: querce-
tin and curcumin. Despite their different 
structure, quercetin and curcumin are two 
polyphenolic phytochemicals with com-
parable pharmacological antioxidant and 
anti-inflammatory activities (Davis, Mur-
phy, and Carmichael n.d.; Liu 2003; Pan-
chatcharam et al. 2006; Phan et al. 2001). 
Both these polyphenols have been pro-
posed as topical therapeutic agents for 
skin irritation and skin barrier function 
recovery in wound healing, because they 
Empty PEG-PEVs
Empty OrPEG-PEVs
QUE liposome
QUE PEG-PEVs
QUE OrPEG-PEVs
138±10
160±11
112±9
152±11
0.30
0.31
0.25
0.23
-11±3
-10±4
-10±4
-11±2
-
-
58±8
56±6
-
-
-
62±6
58±8
CUR liposomes
CUR PEG-PEVs
CUR OrPEG-PEVs
132±8
161±12
188±9
220±13
0.26
0.33
0.34
0.37
-10±3
-13±2
-11±3
-9±4
68±7
71±8
68±7
64±9
79±4
82±9
66±8
65±7
 Empty liposomes 121±8 0.26 -11±2 -
 Sample
MD
(nm±SD)
PI EE
(%±SD)
ZP
(mV±SD)
AE
(%±SD)
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can modulate inflammation and angio-
pathy, the major issues associated with 
impaired wound healing (Gomathi et al. 
2003; MARTIN n.d.; Mohanty et al. 2012; 
Panchatcharam et al. 2006; Sidhu et al. 
n.d.). The cutaneous application of na-
noencapsulated drugs may improve the-
rapeutic effectiveness by extended time 
of local action at higher concentrations, 
and may reduce the risk for systemic side 
effects.
To optimize the maximum amount of 
drug that could be loaded in phospholi-
pid vesicles, a pre-formulation study was 
carried out using several phospholipids 
and different amounts of drug and pho-
spholipids (data not reported). Among 
the tested phospholipids, S75 was found 
to produce the vesicles loading the hi-
ghest amount of both quercetin and cur-
cumin, which was 10 mg/ml. Such con-
centration allowed the bilayer and water 
phase of vesicle dispersion to be satura-
ted and such condition can facilitate drug 
passage across the skin. Indeed, the ma-
ximum drug transfer into the skin takes 
place when the vehicle is saturated with 
the drug, because it is in a state of eleva-
ted thermodynamic activity that confers 
a greater leaving tendency (51, 73). Sa-
turated conditions are therefore prefe-
rable for topical drug delivery systems. 
Conventional liposomes and innovative 
phospholipid vesicles (PEVs) were prepa-
red using a high amount of S75 and the 
same amount of quercetin and curcumin. 
These polyphenols are lipophilic mole-
cules that can localize in the bilayer of 
vesicles, and to stabilize 10 mg/ml of the 
phytodrugs into the lamellar structure, a 
high concentration of lipids (240 mg/ml) 
is needed. Otherwise, drug precipitation 
occurs, especially using curcumin.
Moreover, in PEVs, PEG400 and Oramix 
were added to improve drug solubility 
and diffusion through the skin (Table 1) (5, 
9, 67, 74). They are nonionic surfactants 
(Oramix, HLB =16; PEG400 HLB 20) able 
to increase skin permeation of drugs by 
causing a disordering effect within its in-
tercorneocyte lamellar phase (75). PEVs 
were prepared with and without Oramix 
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to evaluate its possible synergistic effect 
with PEG400 allowing an additional be-
nefit on drug activity. 
In this study, thanks to the use of diffe-
rent and sophisticated techniques such 
as TEM, light scattering, electrophoretic 
measurements and x-ray scattering, we 
gained a precise and detailed picture 
of quercetin and curcumin nanovesicle 
structure, which represents an important 
ground to evaluate their effectiveness in 
vitro and in vivo. 
Liposomes were oligolamellar vesicles 
with spherical shape and homogene-
ous size distribution, whereas PEVs were 
always multilamellar and larger than lipo-
somes. Due to their different chemical 
structure, quercetin and curcumin diffe-
rently affected vesicle features. The cha-
racterization of formulations showed that 
the incorporation of tricyclic quercetin did 
not affect vesicle size, probably because 
its chemical structure and spatial arran-
gement was not able to modify bilayer 
packing. On the contrary, bicyclic curcu-
min caused an enlargement of the vesicle 
curvature radius, an increase in lamellari-
ty and, consequently, in size. In particular, 
curcumin, in liposomes, seems to have 
a more pronounced disturbing effect on 
the polar head amplitude, probably due 
to its more superficial localization in the 
bilayer (76). The presence of curcumin 
enlarged the polar head area and con-
sequently bilayer thickness and curvatu-
re. Such effects were more evident when 
hydrophilic surfactants were used (PEVs). 
Their presence, in synergy with polyphe-
nols, modified the lamellar packing, 
increasing the vesicle size, lamellarity, 
polar head amplitude and, slightly, lipid 
bilayer amplitude, as compared to the 
corresponding liposomes. These physi-
cal rearrangements were combined with 
a reduction of lamellar and water layer 
thickness due to a partial shielding effect 
of these molecules on bilayer surface that 
reduced interbilayer repulsion and their 
consequent distance. 
Given all that, empty and quercetin-loa-
ded liposomes were the smallest vesicles 
with the lowest polar head amplitude, 
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and curcumin OrPEG-PEVs were the lar-
gest ones with the highest polar head am-
plitude, as well as the other OrPEG-PEVs. 
Zeta potential values were similar for all 
the tested formulations due to the pre-
sence of phosphatidylcholine, the main 
component of the bilayer, which is a 
zwitterionic molecule containing the pho-
sphate and choline functional groups: at 
pH near neutrality (∼7) it shows the pre-
valence of charged phosphate group 
imparting a negative value to the vesicle 
surface (50, 77). 
In vitro skin permeation study represents 
a valid and alternative method to select 
effective formulations able to exert opti-
mal properties in vivo. Given the limited 
availability of human tissue and the fact 
that a number of percutaneous investiga-
tions may be too toxic to be carried out 
on living subjects, in vitro animal models 
have been investigated for their useful-
ness in predicting cutaneous and per-
cutaneous absorption mechanisms and 
kinetics. Several studies suggest that pig 
skin can be used as an excellent surroga-
te for human skin in vitro dermal and tran-
sdermal tests (78, 79). In particular, new 
born pig skin is a reliable, feasible mo-
del, superior to other animal species, for 
the evaluation of drug penetration and 
permeation, thanks to the similarity of its 
stratum corneum in terms of lipid compo-
sition, even if it presents a marked diffe-
rence in terms of thickness. New born pig 
stratum corneum is considerably thinner 
than that of adult pigs, and more simi-
lar to that of the human skin, even if the 
number of hair follicles is higher (6, 80). In 
the light of this, in the present work the 
skin permeation ability of QUE and CUR 
nanovesicles was evaluated in vitro using 
new born pig skin. 
Saturated dispersions of QUE and CUR 
(containing 50 mg/ml of PEG and 950 
mg/ml of PBS) were used as controls to 
obtain free drug deposition into the skin 
in the absence of a nanocarrier, exploiting 
only the penetration enhancer ability of 
PEG400. It can improve drug solubilisa-
tion and facilitate its passage through the 
stratum corneum barrier by temporarily 
5. fabbrIcatIon of quercetIn and curcumIn 
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Figure 4. Determination of QUE and 
CUR deposition into skin layers (SC, 
stratum corneum; Ep, epidermis; D, 
dermis) and receptor fluid (RF) after 
24 h of non-occlusive treatment with 
drug dispersions, liposomes and 
PEVs. Each value is the mean±SD of at 
least six experimental determinations. 
No statistical differences (p>0.05) 
were found between samples labelled 
with the same symbol (*, +, #, °).
QUE 
DISP
0
5
10
15
20
25A
cc
um
ul
at
ed
 d
ru
g
 (%
)
30
35
QUE 
LIPO
QUE 
PEG-PEVs
QUE 
OrPEG-PEVs
CUR
DISP
SC Ep D RF
CUR
LIPO
CUR
PEG-PEVs
CUR
OrPEG-PEVs
106
phd program in scienze e tecnologie farmaceutiche -xxvi ciclo-
107
perturbing  interlamellar structure. Using 
control dispersions, drug deposition into 
the skin was 15% in the stratum corneum, 
1.5% in epidermis and 0.2% in the der-
mis. Skin permeation involves diffusion 
across a series of barriers and anatomical 
structures that make difficult drug passa-
ge. Lamellar vesicles, like liposomes and 
PEVs, can facilitate drug diffusion into 
or through the skin, depending on their 
ability to act as penetration enhancers or 
drug carriers. Actually, both liposomes 
and PEVs were able to improve QUE and 
CUR skin deposition, with respect to drug 
dispersions, especially in the stratum cor-
neum where they reached ~28%, ~3% 
in epidermis (except for curcumin Or-
PEG-PEVs) and ~1% in the dermis. These 
findings show that using liposomes and 
PEVs an additional benefit on drug accu-
mulation in the skin can be achieved, as 
they act not only as penetration enhan-
cers, but also as suitable carriers. 
Skin irritation and local inflammation in 
the TPA model occurred within 1-4 h due 
to increased vascular permeability and 
the following development of oedema 
and swelling in the dermis. As a result, 
polymorphonuclear leukocytes migra-
te to the dermis within about 24-48 h 
and may be estimated by the MPO as-
say. Indeed, TPA induces inflammation, 
leukocyte infiltration, accumulation of 
oxygen free radicals and subsequent epi-
dermal damage mimicking some of the 
effects of chronic skin wounds. The ability 
of QUE and CUR nanovesicles to inhibit 
oedema and MPO during TPA treatment 
allowed stopping the biochemical events 
that naturally lead to wound formation. 
The topical administration of polyphe-
nol-loaded nanovesicles achieved an 
important reduction of epidermal loss, 
local vascular permeability and leukocyte 
infiltration.
QUE and CUR dispersions were unable to 
achieve the same biochemical effects on 
TPA-treated tissue: skin appeared infla-
med and damaged, and MPO inhibition 
was not significant (p>0.05). We can state 
that bionanovesicles play a key function 
in actively carrying the phytodrugs to the 
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Table 4. Mouse oedema and myelo-
peroxidase (MPO) values (n=4) and 
relative oedema and myeloperoxidase 
inhibition (I%), obtained after TPA 
treatment followed by application of 
QUE and CUR dispersions, liposo-
mes and PEVs. Symbols * (p<0.05), ° 
(p<0.01) indicate statistical differences 
with respect to TPA-treated mouse; 
symbol # indicates statistical differen-
ce with respect to +.
108
phd program in scienze e tecnologie farmaceutiche -xxvi ciclo-
dermis where they facilitate drug uptake 
by fibroblasts. CUR and QUE promotion 
of wound healing has been previously 
studied, but their intrinsic activity and po-
tential efficacy in carriers were not com-
pared before (62, 63).  Quercetin-loaded 
vesicles were more effective than empty 
vesicles in inhibiting MPO accumulation 
and leukocyte infiltration in damaged tis-
sue, but their ability to reduce oedema 
formation was similar to empty phospho-
lipid vesicles that also possessed a good 
antioedema activity. 
Curcumin vesicles, especiallyCUR 
PEG-PEVs, showed the best ability to re-
duce oedema and MPO activity (91% and 
67%, respectively), not just for its intrinsic 
higher pharmacological activity (marginal 
for curcumin dispersion), but probably 
because this formulation possesses a su-
TPA
Empty OrPEG-PEVs
QUE dispersion
QUE liposomes
QUE PEG-PEVs
10.2±0.76
*5.3±0.63
*5.0±0.51
*5.3±0.55
0
80±6
85±5
74±5
 275±17
277±7
277±8
+°167±9
0
0
59±4
39±3
QUE OrPEG-PEVs
CUR dispersion
CUR liposomes
CUR PEG-PEVs
CUR OrPEG-PEVs
*4.9±0.82
*5.5±0.69
+*7.1±0.36
+*6.5±0.29
#°4.6±0.62
*5.9±0.96
86±8
76±7
50±4
61±3
91±6
70±9
°113±11
+°140±17
244±19
#°86±11
#°90±18
+*201±6
17±3
49±7
11±7
69±4
67±7
27±3
Untreated 4.1±0.13 100 0 100
 Sample
Oedema
(mg)
Oedema I
(%)
MPO I
(%)
MPO
(ng/mg)
109
perior ability to load curcumin and carry 
it across the skin in the damaged tissue, 
potentiating its therapeutic efficacy (72). 
The inhibition of skin damage by curcu-
min nanovesicles may be due to the inhi-
bition of detrimental activity of reactive 
oxygen species (ROS) that leads to a pro-
tective effect on fibroblasts, increasing 
their proliferation and their production of 
collagen and elastin (81). These fibrous 
proteins play a central role in wound he-
aling, being main components of con-
nective tissue that provides a structured 
and organized connective network for the 
regenerating tissue (82, 83). The specific 
mechanism by which polyphenols prevent 
skin ulceration and enhance early regene-
ration of wounds is not exactly explained. 
However, it is commonly recognized that 
several concomitant factors may be invol-
ved. Some research reported the benefi-
cial effect of polyphenols on early repair 
of ulcers due to improvements on cell 
regeneration and collagen synthesis that 
can be in part related to their antioxidant 
and free-radical scavenging activity able 
to reduce cell damage and apoptosis (58, 
66, 82, 83). For the same reason, they 
may also provide a protection of hemato-
poietic system, facilitating the reduction 
of the tissue homeostasis (83). Further, it 
has been reported that they are able to 
increase the synthesis of anti-inflamma-
tory prostaglandins responsible for the 
accelerated healing.
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Figure 5. Histopathological exami-
nation of hematoxylin-eosin stained 
mouse skin section: untreated (A and 
B), TPA-inflamed (C and D) or TPA-in-
flamed and treated with quercetin 
dispersion (E), quercetin liposomes 
(F), curcumin OrPEG-PEVs (G) and cur-
cumin PEG- PEVs (H). Bars represent 
100 m. Intact epidermis (IE), loss of 
epidermis (LE), leukocyte (L), vascular 
congestion (VC), keratinized areas 
(KA) and new epidermis (NE) are ar-
rowed. A magnification (60x, I) of the 
inflamed skin is shown with arrowed 
polymorphonuclear neutrophils (PN), 
eosinophils (E), macrophages (M).
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 5.5. Conclusion
Results on quercetin and curcumin bio-
nanovesicles show their significant an-
ti-inflammatory activity able to inhibit the 
onset of skin wound during the TPA treat-
ment. This protective effect was more re-
levant in curcumin PEG-PEV formulation 
thanks to the excellent ability of the vesi-
cle carrier to increase drug bioavailability 
in the target tissue. Nanoentrapped cur-
cumin prevented the formation of skin le-
sions abrogating the various biochemical 
processes that cause epithelial loss and 
skin damage. Based on the epidemio-
logical evidence and in vivo and in vitro 
studies we can suggest that a daily topi-
cal application of curcumin-loaded nano-
vesicles on patients at higher risk of skin 
wound may provide efficient protection 
against this compliance. 
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6. general conclusIon
In this study skin specific delivery sy-
stems were prepared, characterized and 
subjected to in vitro, ex vivo and in vivo 
studies.
We used a different amount of penetra-
tion enhancer to improve drug incorpo-
ration into the phospholipid bilayered 
vesicles and drug delivery to the skin. In-
deed, results have underlined the ability 
of the studied PEVs to reach these aims. 
Thanks to the presence of the penetra-
tion enhancers, quercetin and curcumin 
were incorporated in high yields into the 
new PEVs. Moreover, the association of 
penetration enhancer to the liposomal 
vesicles has increased drug deposition 
into the skin, thus showing that PEVs 
are potent nanocarriers for skin delivery. 
This research has produced three papers: 
in the first work it has been shown that 
concentrated and densely packed tran-
scutol containing vesicles are valuable 
candidates for topical drug delivery of 
the NSAID diclofenac. These new carriers 
are able to form a gel-like interconnected 
vesicular dispersion that is characterized 
of a viscosity higher than that of water, 
favoring the cutaneous drug deposition 
and interaction with fibroblasts. In vitro 
studies with cells have proved that these 
PEVs are capable of being internalized by 
the 3T3 fibroblasts and, also, of reducing 
the in vitro drug toxicity.
The second paper has highlighted the 
important effects of water miscible co-
solvents, such as propylene glycol, on 
hydrogenated phospholipid vesicle as-
sembly structure. Results showed the pre-
sence of a complex architecture in which 
vesicles are closely packed and intercon-
nected forming a tridimensional structure 
that is responsible for the high viscous/
soft solid like behavior of the system. This 
complex structure facilitates the topical 
application of the formulation (without 
the need of using jellifying polymers that 
would affect the drug release) and incre-
ase the drug residence time at the appli-
cation site.
Results of the third paper has shown 
evidence of an important anti-inflamma-
tory activity of the quercetin- and curcu-
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min-loaded bionanovesicles capable of 
inhibiting the onset of skin wound during 
the TPA treatment. The most protective 
effect was relevant in curcumin PEG-PEV 
formulation thanks to the capability of the 
vesicle carrier to increase drug bioavaila-
bility in the target tissue. Indeed, ex vivo 
penetration and permeation results have 
shown that the presence of a hydrophilic 
penetration enhancer molecule in the for-
mulation is crucial for improving dermal 
delivery of a lipophilic drug such as cur-
cumin or quercetin. 
Summarizing the results of this study, 
PEVs can be a promising formulation for 
(trans)dermal delivery of both hydrophilic 
and lipophilic drugs. 
In conclusion, PEVs are eligible for the 
use as suitable carriers in skin disease tre-
atment.
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